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SUMMARY 
Alzheimer’s disease (AD) is an age-related neurodegenerative disorder that 
affects millions of patients worldwide. The gene encoding various isoforms of the 
brain lipid carrier apolipoprotein (APO) E is the most important genetic risk factor 
for the sporadic form of AD suggesting an important contribution of brain lipid 
metabolism to neurodegenerative processes. However, the mechanism whereby 
brain lipid homeostasis may affect brain health and disease, and the isoform-
specific role of APOE in this process remains highly controversial. 
In my thesis, I focused on the functional characterization of sortilin, a neuronal 
clearance receptor for APOE. Specifically, I hypothesized that sortilin may interact 
with apoE3 to safeguard a protective brain lipid metabolism, and that such 
neuroprotective lipid profile may be lost in the presence of apoE4, the AD risk 
bearing variant of the lipid carrier. To test my hypothesis, I performed comparative 
analyses of lipid profiles in the brain of mouse models with targeted replacement 
of murine Apoe with either human apoE3 or apoE4. In addition, these mice were 
either wildtype or genetically deficient for sortilin. In my studies, I identified 
perturbation in brain levels of docosahexaenoic acids (DHA), the most common 
polyunsaturated fatty acid (PUFA), as well as in endocannabinoids (eCBs), fatty 
acids-based neurotransmitters as a consequence of the APOE and sortilin 
genotypes. I identified the underlying molecular mechanism by showing that 
sortilin binds and stabilizes the fatty acid binding protein 7 (FABP7), an 
intracellular carrier for PUFA and eCBs. FABP7 facilitates the neuronal 
metabolism and activity of these lipids through their action on the PPAR family of 
nuclear hormone receptors. This functional interaction of sortilin and FABP7 in 
lipid metabolism requires the presence of apoE3. Loss of sortilin in apoE3 mice 
impairs sorting and stability of FABP7 and compromises its action in neuronal 
PUFA and eCB homeostasis, resulting in a pro-inflammatory state. Similar 
detrimental effects are seen in the presence of apoE4 that disrupts the ability of 
sortilin to direct intracellular sorting and proper activity of FABP7. 
Taken together, my investigations have identified a unique pathway involving 
sortilin as well as carriers for extracellular and intracellular transport of lipids, 
namely apoE3 and FABP7 that control the anti-inflammatory metabolism of PUFA 
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and eCBs, and how this pathway may support the functional integrity of the brain 
through the action of PPARs. My findings emphasize the relevance of lipids for the 
functional integrity of the human brain, and why aberrant alterations in this 
biological system may contribute to the risk of AD in carriers of the apoE4 
genotype.
  VII 
ZUSAMMENFASSUNG 
Die Alzheimer Krankheit ist eine altersbedingte neurodegenerative Erkrankung, 
die Millionen von Patienten betrifft. Der wichtigste genetische Risikofaktor für die 
sporadische Form der Alzheimer Krankheit ist das Lipidtransportprotein 
Apolipoprotein E (APOE), welches in verschiedenen Isoformen beim Menschen 
vorkommt. Obwohl APOE essentiell für den Lipidstoffwechsel und für 
neurodegenerative Prozesse im Gehirn scheint, ist seine Funktionsweise und 
seine isoform-spezifische Rolle bei der Alzheimer Krankheit immer noch höchst 
umstritten. 
In meiner Doktorarbeit habe ich mich auf die funktionelle Charakterisierung von 
Sortilin, einem neuronalen Rezeptor für APOE fokussiert. Insbesondere habe ich 
die Frage untersucht, ob eine Interaktion von Sortilin mit APOE3 einen protektiven 
Lipidstoffwechsel im Gehirn  gewährleistet und ob eine solche neuroprotektive 
Funktion des Rezeptors bei der Risikovariante APOE4 nicht gegeben ist. Um 
meine Hypothese zu testen, habe ich vergleichende Analysen der Lipidprofile im 
Gehirn von Mausmodellen durchgeführt, welche die menschlichen APOE 
Varianten APOE3 oder APOE4 ausbilden. Darüber hinaus waren diese Mäuse im 
Bezug auf Sortilin entweder wildtypisch oder gendefizient. 
In meinen vergleichenden Studien der Lipide im Gehirn meiner vier Mausmodelle 
identifizierte ich Veränderungen im Stoffwechsel von Docosahexaensäure (DHA), 
der häufigsten mehrfach ungesättigten Fettsäure (PUFA) sowie in 
Endocannabinoiden (eCBs), fettsäurebasierten Neurotransmittern in Abhängigkeit 
von APOE- und Sortilin-Genotyp. Ich konnte den molekularen Mechanismus, der 
dieser Veränderung zu Grunde liegt, weiter aufklären und zeigen, dass Sortilin das 
Fettsäure-Bindeprotein 7 (FABP7) bindet und stabilisiert. FABP7 ist der 
intrazelluläre Transportfaktor für PUFA und eCBs und steuert den neuronalen 
Metabolismus und die Aktivität dieser Lipide. Insbesondere kontrolliert FABP7 die 
Interaktion der eCBs mit nukleären Hormonrezeptoren der PPAR Genfamilie. Die 
Liganden induzierte Aktivierung dieser Rezeptoren bedingt ein 
entzündungshemmendes Genexpressionsprofil im Gehirn. Diese funktionelle 
Interaktion von Sortilin und FABP7 im entzündungshemmenden Fettstoffwechsel 




APOE3-Mäusen stört die korrekte intrazelluläre Sortierung und die Stabilität von 
FABP7 und unterbricht das neuronale PUFA- und eCB-Gleichgewicht. Letzendlich 
führen diese Störungen zu einem Verlust neuroprotektiver Aktivitäten der PPARs 
und bedingen einen pro-inflammatorischen Zustand des Gehirns. Ähnliche 
pathologische Auswirkungen zeigten sich auch in Anwesenheit von APOE4. 
Anders als bei der Interaktion mit APOE3, führt die  Bindung von APOE4 an 
Sortilin zu einer fehlerhaften Akkumulation des Rezeptors im Endozytoseweg der 
Zellen und zum Verlust seiner FABP7 Interaktion. 
Zusammenfassend haben meine Untersuchungen einen neuartigen zellulären 
Mechanismus im Lipidstoffwechel des Gehirns aufgedeckt, der die Wirkungsweise 
von APOE4 als Hochrisikofaktor der Alzheimer Krankheit miterklären könnte. 
Dieser Stoffwechselweg umfasst die Interaktion des neuronal Rezeptors Sortilin 
mit extrazellulären (APOE) und intrazellulären (FABP7) Transportproteinen für 
PUFAs. Dieser Stoffwechselweg ermöglicht die entzündungshemmende Wirkung 
von PUFA und eCBs über PPARs im Gehirn. Dieser neuroprotektive 
Stoffwechselweg wird durch die Anwesenheit von APOE4 gestört, da es die 
Funktionsweise von Sortilin blockiert. 
Zusammengefasst unterstützen meine Ergebnisse die Bedeutung des neuronalen 
Lipidstoffwechsels für die funktionelle Integrität des menschlichen Gehirns und 
geben eine mögliche Erklärung für Störungen des Lipidstoffwechsels als Ursache 
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1. INTRODUCTION 
1.1. Alzheimer’s disease (AD) 
1.1.1. Clinical and neuropathology features of AD 
At the beginning of the twentieth century, Alois Alzheimer reported the case 
of a woman who died a few years after developing a clinically unusual form of 
dementia at age 51. Later, similar cases were reported and led to the recognition 
of this condition as unique disease, termed Alzheimer’s disease (AD) (Berchtold 
and Cotman 1998). After more than one hundred years, huge strides have been 
made to uncover its underlying mechanisms but still to date no cure has been 
developed. Today, AD is the most common form of age-related dementia. The 
disease begins with a gradual decline of memory after which other symptoms of 
behavioral and cognitive deficits take over. Initially, AD is characterized by short-
term memory loss that is difficult to diagnose because it may also be attributed to 
ageing and stress. However, as the disease progresses, other forms of cognition 
become impaired resulting in difficulties in thinking, in disorientation and in mood 
swings. Additional serious symptoms such as difficulty in speaking as well as 
behavioral changes can interfere with the patient performing everyday tasks (Rao 
et al. 2014). The occurrence of these symptoms is the consequence of multiple 
lesions in different brain regions. In the brain of AD patients, progressive disruption 
of vital processes in neurons result in loss of synaptic activity and eventual 
neuronal cell death (Selkoe 1991). For this reason, AD belongs to the category of 
neurodegenerative disorders characterized by chronic loss of structure and 
function of neurons. At late stages of the disease, AD patients display significant 
cerebral atrophy with a decrease in brain volume (Blennow et al. 2001). The 
decrease in cortical thickness can be detected by magnetic resonance imaging 
(MRI) and correlated to the progression of cognitive dysfunction (Putcha et al. 
2011). Several mechanisms have been implicated in this drastic loss of neuronal 
connections and ultimate cell death, including protein deposits forming 
extracellular amyloid plaques and intracellular neurofibrillary tangles, as well as 
brain inflammation, oxidative stress, and mitochondrial dysfunction (Blennow et al. 
2001). A major culprit of AD is the amyloid-β (Aβ) peptide, a principal neurotoxic 




around neurons. Aβ is produced by proteolytic breakdown of the amyloid 
precursor protein (APP), a type-1 transmembrane protein expressed and 
proteolytically processed in many cell types. Functions have been assigned both 
to the full-length precursor but also to the proteolytic breakdown products of APP. 
The extracellular domain of full-length APP binds various extracellular matrix 
components essential for its activity in cell-matrix adhesion (Kibbey et al. 1993) 
(Beher et al. 1996). In addition, APP has a trophic function as hippocampal 
neurons deficient in APP show decreased viability and retarded neurite 
development (Perez et al. 1997). In support of the role for APP in neuronal viability 
and function, APP knock-out mice exhibit a decrease in locomotor activity (Zheng 
et al. 1995). In a physiological process occurring in many cell types, full-length 
APP can also be proteolytically processed, forming new protein fragments with 
additional functions. In detail, APP can follow two alternative processing fates, 
amyloidogenic or non-amyloidogenic, depending on whether neurotoxic Aβ is 
produced or not. In the amyloidognenic pathway, APP is cleaved by β-secretase 
leading to the secretion of sAPPβ. Then, the γ-secretase complex cleaves the 
remaining membrane-anchored carboxy-terminal fragment (CTFβ), releasing the 
Aβ peptide and the APP intracellular domain (AICD) (Figure 1.1). Cleavage by γ-
secretase is imprecise and generates Aβ peptides with varying amino acid 
lengths. The predominant forms are Aβ40 and Aβ42 (Haass et al. 2012). The 
Aβ42 peptide is more prone to oligomerization and aggregation than Aβ40, 
suggesting that the imprecise γ-secretase cleavage influences neurotoxicity of the 
produced Aβ species (Haass and Selkoe 2007). Ultimately, Aβ peptides form 
insoluble amyloid fibrils, that accumulate as senile plaques (Hardy and Higgins 
1992). Of note, the extent of plaque deposition does not correlate well with the 
cognitive decline in AD patients (Sloane et al. 1997) (Crystal et al. 1988). Rather, it 
is the concentration of toxic soluble Aβ oligomers that are better correlated with 
the AD symptoms. Thus, current hypotheses suggest that the toxic insult of these 
soluble oligomers cause synaptic dysfunction and neuronal death in AD (Selkoe 
2008) (Kamenetz et al. 2003). Production of Aβ is prevented in the non-
amyloidogenic pathway when APP is initially processed by α-secretase activity, 




Aβ peptide and produces the soluble extracellular fragment, sAPPα and the 
membrane-anchored carboxyterminal fragment α (CTFα) (Figure 1.1).  
Figure 1.1: Amyloidogenic and non-amyloidogenic processing of the amyloid precursor 
protein (APP).  
In the amyloidogenic pathway (to the right), APP is processed by β-secretase, releasing soluble 
APPβ (sAPPβ) and the membrane-anchored carboxy-terminal fragment β (CTFβ). Further 
processing of CTFβ by γ-secretase produces the neurotoxic Aβ peptide and the APP intracellular 
domain (AICD). In the non-amyloidogenic pathway (to the left), APP is cleaved by α-secretase 
activity, which destroys the Aβ peptide and produces sAPPα and the membrane-anchored 
fragment CTFα. 
The underlying mechanisms whereby APP functions are coordinated between its 
full-length form and the proteolytic cleavage products remain unclear (Müller and 
Zheng 2012). However, it is well appreciated that mechanisms that increase APP 
processing to Aβ (amyloidogenic processing), or that impair catabolism of the 
peptide in the brain are responsible for its adverse aggregation in the brain 
parenchyma and consequently, its neurotoxic deposits in AD (Pearson and Peers 
2006). 
1.1.2. Epidemiology and risk factors of AD 
Today, around 50 million people worldwide are affected by age-related dementia 
and this number is expected to increase even more as people live longer and no 
cure or treatment is available (World Health Organization, 2018). The combined 
economic and social burden of AD is enormous. This devasting disorder 
profoundly affect the lives of patients and their families (Winblad et al. 2016). AD 




attention and health care costs are allocated to this disease as it is becoming a 
major public health problem. AD is a complex and heterogeneous disorder 
affected by multiple risk genes and environmental factors. Based on heritability 
(familial vs sporadic) and age of onset (early vs late), AD can be classified into 
different disease types. Among these, the early-onset familial form of AD (EOAD) 
accounts for less than 1% of AD cases. In EOAD, affected people carry 
dominantly inherited mutations in 3 genes, encoding for amyloid precursor protein 
(APP), presenilin 1 (PSEN1) or presenilin 2 (PSEN2) (Campion et al. 2002). 
Presenilins are subunits of the γ-secretase complex. Recently, potentially 
pathogenic sequence variations in SORL1 were found in EOAD patients as well 
(Pottier et al. 2012) (Nicolas et al. 2016) (Verheijen et al. 2016). Mutations in 
familial disease genes typically accelerate the cleavage of APP and lead to an 
increase in Aβ42 levels or in the Aβ42/Aβ40 ratio (Scheuner et al. 1996). 
However, the vast majority of patients over the age of 65 are afflicted by the late-
onset sporadic form of the disease (LOAD), caused by a combination of genetic 
and environmental risk factors (Rao et al. 2014).  
While it has been established that familial EOAD is primarily determined by 
genetics, the aetiology of sporadic LOAD remains to be fully elucidated. A large 
number of environmental factors have been associated with increased or 
decreased risk for the sporadic form of AD. Ageing is the obvious determinant of 
AD risk as there is an exponential increase in dementia in individuals 65 years and 
older (Evans et al. 1989). Several studies have shown that AD patients have fewer 
years of education and higher prevalence of heart disease than persons without 
AD (Luchsinger et al. 2001). Moreover, obesity and diabetes increase the risk of 
AD (Profenno et al. 2010). The Mediterranean diet rich in unsaturated lipids 
contained in olive oil, vegetables and fish is correlated with a reduction in the 
incidence of AD (Scarmeas et al. 2011), while smoking, lack of physical activity, 
and hypertension increase it. Still, these environmental factors do not usually 
provide sufficient sensitivity and/or specificity to be employed as predictive risk 
markers of the disease (Reitz, Brayne, et al. 2011).  
Even as LOAD risk is associated with environmental factors, it still involves a 
strong genetic component. Genome-wide association studies (GWAS) have 




identifying multiple genetic risk loci. Among those risk genes are, CLU, encoding 
an apolipoprotein involved in lipid transport, PICALM  with a role in trafficking of 
synaptic vesicles (Harold et al. 2009), and TREM2, encoding a receptor that 
activates microglial response (Guerreiro et al. 2013) (Hampel et al. 2013). 
Furthermore, SORL1, encoding a neuronal sorting receptor for APP termed 
SORLA has been repeatedly associated with LOAD in GWAS studies (Lambert et 
al. 2013) (Miyashita et al. 2013). SORL1 was initially implicated in LOAD due to 
the fact that SORLA levels were decreased in the brain of AD patients compared 
with healthy controls (Scherzer et al. 2004). Later, it had been shown that several 
allelic variants in the SORL1 gene are causally linked to the pathogenesis of AD 
by altering APP trafficking and consequently increasing Aβ production (Rogaeva 
et al. 2007). Typically, LOAD-associated risk variants in SORL1 impair its 
transcription, splicing or translation efficiency and likely confer LOAD risk by 
reducing SORLA levels in the brain of affected individuals.  
1.1.2.1. The apolipoprotein E 
In recent years, the one gene that has been consistently found to be associated 
with sporadic LOAD across multiple ethnicities is APOE, the gene encoding for 
apolipoprotein (APO) E (Corder et al. 1993) (Harold et al. 2009).  
APOE is a glycoprotein highly expressed in the central nervous system (CNS), 
predominantly by astrocytes but also by microglia and neurons after injury (Xu et 
al. 2006) (Pitas et al. 1987) (Grehan et al. 2001). APOE is a lipid carrier.  It is 
secreted into the brain interstitial fluid where it is lipidated, forming discoid-shaped 
lipid particles that structurally resemble high-density lipoprotein found in the 
circulation. Lipid-loaded APOE deliver essential lipids to both neurons and glia via 
binding to endocytic APOE receptors on the surface of target cells (Holtzman and 
Herz 2012) (Figure 1.2).  
In contrast to many other species including rodents, humans have not one but 
three variants of the APOE gene. These human gene variants differ by two single 
nucleotide polymorphisms (SNPs), encoding three common isoforms, namely 
apoE2 (cys112, cys158), apoE3 (cys112, arg158), and apoE4 (arg112, arg158). 
The respective frequencies of these gene variants in the human population are 




dramatically increased to ~40% in patients with AD. Although all three APOE 
isoforms differ by only one or two amino acids, these changes alter the APOE 
structure and function significantly by changing its ability to bind lipids and/or 
APOE receptors (Corder et al. 1993) (Farrer et al. 1997).  
 
Figure 1.2: APOE metabolism in the brain. 
APOE is primarily produced by astrocytes and lipidated in the extracellular space to form 
lipoprotein particles. APOE-containing lipoprotein particles deliver lipids to neurons that mediate 
cellular uptake via a structurally diverse class of endocytic APOE receptors. 
The most significant LOAD risk gene is the apoE4 isoform. This allele dramatically 
increases the risk of AD at an earlier age of onset in a gene dose-dependent 
manner. Individuals carrying the homozygous apoE4 allele face an eight times 
higher risk of developing LOAD as compared to non-carriers. In contrast, the rare 
apoE2 allele seems to have a protective effect over the common apoE3 allele 
(Corder et al. 1993). So far, the molecular mechanisms whereby apoE4 
constitutes a major risk factor for LOAD remains controversial. Conceptually, 
causative mechanisms may entail a gain of neurotoxic functions for apoE4, such 
as increasing the propensity of Aβ aggregation or disturbing brain activities. 
Alternatively, apoE4 may exhibit a loss of neuroprotective activities seen with 
apoE3, such as supporting mitochondrial function, neurogenesis, or brain lipid 
metabolism (Liu et al. 2013). One popular hypothesis states that APOE may 
controls Aβ production and deposition in an isoform specific manner. For example, 
APOE binds Aβ and mediates its cellular clearance in a isoform-specific manner, 




clearance as compared with apoE3 (LaDu et al. 1994) (Castellano et al. 2011). 
However, there is also growing evidence to support additional roles for APOE in 
the onset and progression of AD. With relevance to my thesis project, several lines 
of evidence suggest Aβ-independent roles for APOE in AD pathogenesis through 
its isoform-specific effects on brain lipid metabolism. 
1.1.3. Aberrant brain lipid homeostasis as cause of AD 
Alois Alzheimer originally described three pathological hallmarks in the brain of 
Auguste Deter. The first two features are the well-studied neurofibrillary tangles 
and senile plaques. The third feature seen were intracellular lipid deposits that 
have not received much attention, perhaps due to the lack of appropriate analytical 
tools (Foley 2010). It is only in recent years that advancements in the field of 
lipidomics has provided strong evidence that multiple factors are involved in the 
pathology of AD where lipid homeostasis appears to be an essential contributor. 
The APOE genotype has repeatedly been linked to Aβ metabolism, one of the 
neuropathological hallmarks of AD. These investigations led to important 
discoveries about the pathophysiological relevance of soluble oligomeric and/or 
insoluble plaque-associated forms of Aβ in AD. However, clinical trials that 
focused on targeting Aβ production and/or accumulation have consistently failed 
(Cummings et al. 2014) and major pharmaceutical companies are abandoning 
their efforts to find new drugs for the treatment of AD. Lack of success may be 
attributed to many factors but the strategy to target Aβ towards a cure for AD is 
currently under question and new disease mechanisms are being considered. 
Alzheimer’s disease is a complex and multifactorial disease and experimental 
evidence supporting Aβ-independent causes of AD pathology is growing steadily. 
This statement particularly concerns hypotheses that suggest isoform-specific 
effects of APOE on brain lipid metabolism that may have protective versus 
adverse effects on brain health and the risk of AD.  
Lipids have major roles in numerous biological systems, including cell membrane 
composition, energy storage, and cell signaling. The brain is the most lipid-rich 
organ in the human body and lipids are particularly relevant for brain health and 
function (Wood 2012). Thus, lipid alterations in the brain or in peripheral tissues 




(Adibhatla and Hatcher 2007). Cholesterol is the most studied lipid in the brain 
because of its abundance and de novo synthesis in the brain, likely reflecting the 
importance of cholesterol for CNS structure and function (Pfrieger and Ungerer 
2011). Cholesterol in the brain is mostly present in the myelin sheaths, as well as 
in the lipid bilayer of the plasma membrane and endocytic vesicles of glial cells 
and neurons (Pfrieger 2003). Cholesterol derived from APOE-containing 
lipoproteins, produced by glia cells is essential for synaptogenesis (Mauch et al. 
2001). Along these lines, studies have linked cholesterol metabolism to AD 
pathogenesis, for example by documenting altered plasma concentrations of 
brain-specific but also peripherally produced oxysterols in AD patients compared 
to non-demented subjects (Kölsch et al. 2004). Epidemiological studies have 
shown a protective effect of statins (cholesterol synthesis inhibitor) on the 
development of dementia (Jick et al. 2000) (Wolozin et al. 2007). Moreover, higher 
or lower cholesterol, the main component in the lipid raft, increases or decreases 
amyloidogenic processing, respectively, possibly by regulating the accessibility of 
β-secretase to its substrate APP in the lipid raft (Ehehalt et al. 2003) (Tarabal et al. 
2007) (Marquer et al. 2011).  Sphingolipids are another class of lipids also altered 
in the AD brain. The simplest form of sphingolipids are ceramides. They are 
composed of sphingosine, an aliphatic amino-alcohol, and a fatty acid. 
Sphingolipids with a more complex structure include cerebrosides, sulfatides, and 
gangliosides. Compared to control cases, AD patients show a decrease in 
gangliosides in the frontal and temporal cortices. Since gangliosides are markers 
of axodendritic arborization, these data suggest that the neuronal loss in AD brains 
may be responsible for the lipid alteration seen (Kracun et al. 1992) (Svennerholm 
and Gottfries 1994). In contrast, ceramides are increased in AD brain, probably 
because they act as second messenger molecules that regulate cell apoptosis and 
Aβ production (He et al. 2013).  
APOE, the most important AD risk gene encodes a lipid transporter, underscoring 
the relevance of lipids for brain pathophysiology. In addition to APOE, GWAS have 
identified several other genes associated with AD risk that function in lipid or 
lipoprotein metabolism, including those encoding for the apolipoprotein clusterin 
(CLU) and the cholesterol transporter ATP binding cassette transporter A7 




1.2. The sorting receptor sortilin 
1.2.1. Structure and function of VPS10P-domain receptors  
Lipids are supplied to brain cells via uptake of APOE-containing lipoprotein 
through APOE receptors. These receptors can influence APOE functions and, 
thus, are important for normal brain lipid metabolism but likely also for lipid 
alterations seen in AD. Several APOE receptors have been identified in the brain 
including the low-density lipoprotein (LDL) receptor (LDLR), the LDLR-related 
protein 1 (LRP1), the apolipoprotein E receptor 2 (ApoER2), and the very-low-
density lipoprotein receptor (VLDLR). LDLR is mainly expressed in glia cells 
whereas LRP1 expression is neuronal (William Rebeck et al. 1993) (Rapp et al. 
2006). Still, both LDLR and LPR1 are important for Aβ clearance as decreased 
expression of either receptor is  associated with increased amyloid deposition in 
mouse models (Cao et al. 2006) (Van Uden et al. 2002). LRP1 KO mice also show 
a decrease in cholesterol levels in forebrain tissues when compared to WT 
animals (Liu et al. 2007). Interestingly, ApoER2 and VLDLR bind the signaling 
protein reelin resulting in protection from neurotoxicity by preventing the 
detrimental effects of Aβ on long-term potentiation (Durakoglugil et al. 2009). The 
same impaired synaptic activity is seen when apoE4 binds ApoER2, antagonizing 
reelin signaling at the neuronal cell surface (Chen et al. 2010). 
Although several receptors had been implicated in APOE uptake in neurons, no 
alterations in brain APOE levels were seen in mouse models lacking any of APOE. 
The situation is different for sortilin, a recently identified neuronal receptor for 
APOE-containing lipoproteins (Carlo et al. 2013). Sortilin is a member of a class of 
intracellular sorting receptors, named vacuolar protein sorting 10 protein (VPS10P) 
domain receptor. VPS10P domain receptors are type-1 transmembrane 
proteins conserved throughout evolution that share a common protein module in 
their extracellular domain, the VPS10P domain. This 700 amino acids domain was 
initially identified in the vacuolar protein sorting 10 protein (VPS10P) 
in Saccharomyces cerevisiae. The yeast sorting receptor VPS10P delivers newly 
synthesized lysosomal enzymes from the Golgi to the vacuole, the yeast lysosome 
(Marcusson et al. 1994). In mammals, the VPS10P domain protein family consists 




(SORLA) as well as sortilin-related receptors CNS expressed (SORCS) 1, -2, and 
-3 (Figure 1.3). All the members of this family contain a large amino terminal 
luminal/extracellular domain, encompassing the VPS10P domain, followed by a 
single transmembrane domain and a short cytoplasmic tail at the carboxyl 
terminus. Sortilin is the only protein where extracellular domain only consists of a 
VPS10P domain. Other family members have additional structural motifs, such as 
leucine-rich domains, complement-type repeats, epidermal growth factor (EGF)-
type repeats and fibronectin type III domains, all of which are involved in protein-
protein interaction. The APP binding site in SORLA is located in the complement-
type repeats in the extracellular domain, which is essential for shuttling APP to the 
TGN and to protect it from processing (Andersen et al. 2006). A further module is 
the β-propeller, which is involved in the regulation of ligand binding (Figure 1.3). 
Based on crystal structures, the VPS10P domain of sortilin and SORLA consist of 
a ten-bladed β-propeller that forms a large conical tunnel in which ligands bind 
(Quistgaard et al. 2009) (Kitago et al. 2015). Of note, the familial SORL1 mutation 
G511R is located in the VPS10P domain of SORLA and disrupts the binding of Aβ 
to SORLA, resulting in impaired lysosomal targeting of Aβ by the mutant receptor 
(Caglayan et al. 2014). The short cytoplasmic tails of the VPS10P-domain 
receptors contain internalization signals and prototypical recognition motifs for a 
number of cytosolic adaptor proteins that traffic these receptors and their cargo 
between the cell surface and various intracellular compartments (Willnow et al. 
2008). 
The intracellular fate of sortilin and SORLA was intensively studied. Sortilin and 
SORLA predominantly localize to the late Golgi compartment, with only a minor 
fraction of the receptor pool being present at the cell surface. From the cell 
surface, SORLA and sortilin may deliver internalized ligands via early and late 
endosomes to lysosomes for catabolism or retrogradely from early endosomes 
back to the TGN for resecretion. Information on the trafficking paths of SORCS 
receptors is limited. SORCS1’s subcellular localization varies between its splice 
forms. But the receptor is mostly implicated in the delivery of cargo to lysosomes. 
SORCS2 was shown to be equally distributed between intracellular organelles and 
the plasma membrane. Instead, localization of SORCS3 depends on the cell line 




Chinese hamster ovary (CHO) cells resulted in a predominant cell surface 
exposure of the receptor and a low internalization rate (reviewed in (Hermey 2009) 
(Willnow et al. 2008)) (Westergaard et al. 2005) (Nielsen et al. 2008).   
 
Figure 1.3: Structural organization of the vacuolar protein sorting 10 protein (VPS10P) 
domain receptor family.  
Sorting protein-related receptor with A-type repeats (SORLA), sortilin, sortilin-related receptors 
CNS expressed (SORCS) 1, -2, and -3 and VPS10P (Saccharomyces cerevisiae) are type-1 
transmembrane receptors that share a common extracellular domain, the VPS10P domain. Some 
receptors of the family carry additional functional domains depicted here. 
Sortilin and SORLA are trafficked between biosynthetic and endocytic 
compartments through binding to a number of cytosolic adaptor proteins, including 
AP-1 and 2 (adaptor proteins 1 and 2), GGA-1,-2,-3 (Golgi-localizing, γ-adaptin ear 
homology domain, ARF-interacting proteins), PACS1 (phosphofurin acidic cluster 
sorting protein 1), and the retromer complex. SORLA binds AP-2 protein for its 
internalization (Nielsen et al. 2007). Its intracellular transport between Golgi and 
endosomes is regulated by AP-1 and GGA for anterograde transport from the TGN 




for retrograde transport from endosomes to TGN (Schmidt et al. 2007) (Burgert et 
al. 2013). Retromer binding results in a retrograde sorting of SORLA, reducing 
APP processing in endosomes. In contrast, GGA interaction defines anterograde 
sorting of the receptor and its cargo Aβ to lysosomes for catabolism of the peptide 
(Dumanis et al. 2015).  
1.2.2. Mammalian VPS10P domain receptors in health and disease 
VPS10P domain receptors bind a wide variety of ligands, including neurotrophins, 
various tyrosine kinase receptors, synaptic adhesion and transmission molecules, 
and they mediate sorting of these ligands between different subcellular 
compartments. VPS10P domain receptors are genetically or functionally 
implicated in a broad spectrum of human diseases including metabolic 
disturbances. Thus, SORLA is associated with obesity (Smith et al. 2010) (Parks 
et al. 2013), sortilin with hypercholesterolemia (Kathiresan et al. 2008) (Muendlein 
et al. 2009), whereas SORCS1 and 3 are associated with type-2 diabetes 
(Granhall et al. 2006) (Clee et al. 2006). In addition, these receptors are 
associated with neurodegenerative and psychiatric diseases, in line with their 
predominant expression in the developing and adult mammalian nervous system. 
Several members of this gene family have been associated with AD, foremost 
SORLA. Numerous studies have revealed two distinct molecular mechanisms by 
which SORLA acts as a risk factor in AD. Firstly, SORLA was shown to interact 
with APP affecting its intracellular transport from endosomal compartments back to 
the TGN, essentially blocking proteolytic processing into Aβ. Thus, overexpression 
of SORLA reduces the number of APP molecules subjected to amyloidogenic 
processing and reduces Aβ production (Andersen et al. 2005) (Schmidt et al. 
2007) (Offe et al. 2006) (Rogaeva et al. 2007). Secondly, SORLA interacts with 
newly generated Aβ peptides in endosomal compartments and sorts Aβ to the 
lysosome for degradation (Caglayan et al. 2014). The role of SORLA as a negative 
regulator of APP processing was supported by correlating low levels of SORLA in 
mouse models and AD patients with enhanced Aβ deposition (Andersen et al. 
2005) (Dodson et al. 2008) (Rohe et al. 2008).  
Although the mechanisms explaining the association of SORCS receptors with AD 




SORCS1, SORCS2, and SORCS3 are also associated with the risk of LOAD 
(Reitz, Tokuhiro, et al. 2011) (Liang et al. 2009) (Reitz et al. 2013). In addition, 
SORCS2 is implicated in a number of psychiatric diseases, including bipolar 
disorder and schizophrenia (Christoforou et al. 2010), and in the protection of 
neurons from oxidative stress following epilepsy (Malik et al. 2019). 
The VP10P domain receptor with relevance to AD studied in my PhD thesis is 
sortilin. Sortilin was originally identified as a potential lipoprotein receptor in human 
brain extract (Petersen et al. 1997). Subsequent studies showed that this receptor 
not only binds lipoproteins (Nilsson et al. 2008) but several other ligands relevant 
for brain health and disease, particularly neurotrophins and their receptors. 
Neurotrophins are soluble growth factors that mediate neuronal survival through 
signaling via tropomyosin receptor kinases (Trk). Sortilin affects neurotrophic and 
apoptotic processes in the brain by both controlling the release of pro-forms of 
neurotrophins (pro-NT) (Chen 2005) and by sorting of TrK receptors A, B ,and C 
(Vaegter et al. 2011). In addition to Trk receptors, the effect of all neurotrophins is 
regulated by the receptor p75NTR. Sortilin was shown to form a co-receptor with 
p75NTR that specifically recognizes pro-NTs to induce apoptosis in cultured 
neurons (Nykjaer et al. 2004) and in vivo (Jansen et al. 2007). This process is 
pathophysiologically relevant, since release of pro-NTs is increased in AD, 
implicating sortilin-mediated neurotrophin regulation in age-related 
neurodegeneration (Fahnestock et al. 2001).  
Other studies suggest a more direct role for sortilin in amyloidogenic processing by 
regulating the levels of Aβ and senile plaque burden in the brain of AD mouse 
models. In detail, sortilin was shown to bind APOE and to mediate neuronal 
catabolism of APOE- bound Aβ complex. A role for sortilin in brain APOE 
metabolism was supported by the aberrant accumulation of APOE in the brain of 
mice lacking this clearance receptor (Carlo et al. 2013). Besides regulating Aβ 
clearance in the brain, sortilin has also been proposed to increase Aβ production 
by trafficking APP (Gustafsen et al. 2013) or the β-secretase BACE1 (Finan et al. 
2011).  
In addition to a potential function of sortilin in AD, the receptor may also play a 




degeneration (FTLD). FTLD is characterized clinically by dementia with prominent 
behavioral alterations (Cairns et al. 2007). A major cause of FTLD is mutations in 
the progranulin (GRN) gene. Most GRN mutations results in haploinsufficiency of 
PGRN, suggesting that PGRN has a protective role in the brain (Baker et al. 2006) 
(Gass et al. 2006). PGRN is an actively secreted glycoprotein precursor of 
granulin with anti-inflammatory properties (Chitramuthu et al. 2017). Sortilin 
regulates PGRN levels by mediating PGRN endocytosis, delivering it to lysosomes 
for degradation (Hu et al. 2010).  
1.2.3. Role of sortilin in lipid homeostasis 
While the role of sortilin in the brain received major attention, new studies have 
emerged that suggested potentially important functions for this receptor in 
peripheral metabolic tissues as well. Thus, SORT1, encoding sortilin, showed a 
genome-wide association with hypercholesterolemia and the risk of myocardial 
infarction in multiple GWAS (Kathiresan et al. 2008) (Willer et al. 2008). The 
underlying molecular mechanism whereby sortilin may control plasma cholesterol 
levels remains highly controversal. Receptor-mediated reduction of plasma 
cholesterol levels may be achieved by sortilin acting as a lipoprotein receptor in 
the liver that mediates hepatic clearance (Strong et al. 2012) of circulating 
cholesterol-rich lipoproteins. An alternative hypothesis argues that sortilin reduces 
plasma cholesterol levels by facilitating intracellular degradation of newly produced 
lipoprotein particles (Musunuru et al. 2010). On the other hand, other studies 
suggested that sortilin may increase (rather than decrease) cholesterol levels by 
reducing release of cholesterol-rich lipoprotein particles from the liver (Kjolby et al. 
2010) or by acting as a sorting receptor for PCSK9, facilitating its secretion from 
hepatocytes. PCSK9 binds LDLR and causes its lysosomal degradation, resulting 
decreased uptake of circulating cholesterol-rich lipoproteins (Gustafsen et al. 
2014). 
New studies from the Willnow lab now suggest that sortilin may not only act as a 
lipoprotein receptor in the liver. Rather, it may have a similar function in neurons in 
the brain, an activity that may play a central role in normal brain lipid metabolism 
but also in APOE-dependent risk of AD. In detail, studies documented the ability of 




mice lacking sortilin accumulate murine APOE, possibly due to the impaired 
clearance of the apolipoprotein by neurons lacking this APOE receptor (Carlo et al. 
2013). An important role for sortilin as a neuronal APOE receptor was also 
supported by alterations in sulfatide levels seen in the brain of receptor-deficient 
mice. Sulfatides, are a major class of lipids found in the myelin sheath of axons, 
They are believed to be extracted by APOE-containing lipoproteins and delivered 
to neurons for clearance. In support of the role of sortilin in APOE metabolism, 
sortilin knock-out mice show an increase in sulfatides in the their brain compared 
to the wild-type mice (Carlo et al. 2013). The same result of increased sulfatides 
levels is also seen in the brain of mice lacking murine APOE (Han et al. 2003).  
Taken together, these studies suggested sortilin as the main receptor for uptake of 
APOE in neurons in the brain, and its potential contribution to brain lipid 
metabolism and the associated risk of AD. However, the mouse studies on APOE 
and brain lipid metabolism described above were all performed in wild-type and 
receptor mutant mice expressing murine Apoe. Thus, the relevance of sortilin for 
metabolism and action of human APOE variants, specifically for the risk of AD 
seen with apoE4 as compared with apoE3 were not answered by these studies. 
Clarifying this important question was the major aim of my thesis project. 
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2. AIM OF THE STUDY 
AD is the most common form of age-related dementia with the brain lipid 
transporter APOE being the most well-known risk factor for the sporadic form of 
the disease. Lipids play crucial roles in brain physiology and possibly in the 
occurrence of AD. However, the exact role for APOE in these processes remains 
poorly understood. Sortilin is the main APOE receptor in neurons, mediating the 
uptake of APOE-containing lipoprotein particles in these cells in vitro and in vivo 
and may provide explanatory models for the role of neuronal lipid metabolism in 
brain health and disease. Still, the relevance of sortilin for human APOE isoforms 
specific effects on brain (patho)physiology remain unexplored. Accordingly, it was 
the aim of my PhD project to elucidate the cellular and molecular mechanisms 
whereby sortilin may impact APOE-isoform specific mechanisms in brain lipid 
profiles and promote protective or adverse effects of the lipid metabolism in AD. 
To do so, I made use of targeted replacement mice expressing human apoE3 or 
apoE4 instead of the murine protein and crossed them with mouse models either 
wild-type or genetically deficient for sortilin. Applying targeted lipidomics and 
functional investigations of the lipid metabolism in these mouse models in vivo and 
in neurons derived thereof in vitro, and corroborating my findings in specimens 
from AD patients, I aimed at a better understanding of why apoE4 is the main risk 
for sporadic AD and what the functional relevance of sortilin and lipids in this 
process may be. 
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3. MATERIALS AND METHODS 
3.1. Reagents 
3.1.1. Oligonucleotides 
Table 3.1: List of DNA primers used for genotyping PCR. 
Gene Primer orientation Primer sequence 
Sortilin 
Sort f2 GGG ACC AAA GGG CTA GAT TGC 
Sort r2 TCC GAA GGA GAC ACT CAC AAT TC 
bGH poly A for ATG CGG TGG GCT CTA TGG CTT CTG 
 
Table 3.2: List of TaqMan probes used for genotyping. 
Target SNP (minor/major variant) Assay ID 
rs429358 (C/T) C___3084793_20 
rs7412 (T/C) C____904973_10 
 
Quantitative real-time PCR (qRT-PCR) was performed using either TaqMan 
probes ordered from Thermo Fisher or SYBR green dye and DNA primer ordered 
from Qiagen. 
Table 3.3: List of TaqMan probes used for qRT-PCR. 
Gene Assay ID 
Actb  Mm02619580_g1 
















Table 3.4: List of DNA primer used with SYBR green dye for qRT-PCR. 






All peroxidase labeled secondary antibodies for Western blotting were purchased 
from Sigma-Aldrich and used at the dilution 1:5000. Fluorophore-conjugated 
secondary antibodies for immunofluorescence were purchased from Thermo 
Fischer Scientific (Alexa Fluor 647 Dye) and used at the dilution 1:1000. 
Table 3.5: List of primary antibodies used in this study. 
Target protein Commercial provider Catalogue number Dilution Application 
Rab5  Cell Signaling #2143  1:500 IF 
Rab11  Cell Signaling #5589  1:500 IF 
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Tubulin abcam ab6046  1:1000 WB 
FABP7  Millipore ABN14  1:1000 WB 
GAPDH  Genetex GTX627408-01  1:1000 WB 
APOE Millipore AB947  1:1000 WB 
Sortilin  BD Transduction Lab. 612101  1:1000 WB 
FABP5  Biovendor RD181060100  1:1000 WB 
TUJ1  Sigma-Aldrich T8578  1:1000 WB 
Sortilin  R&D Systems AF2934  1:500 IF 
Myc tag Origene TA150121  1:500 IF 
BrdU Linaris LOB0030G  1:500 IH 
*IF, immunofluorescence; WB, Western blotting; IH, immunohistology 
3.1.3. Plasmids 
Expression construct for murine FABP7 with Myc-DDK tag was bought from 
Origene (MR200772). Instead, the expression constructs for human apoE3 and 
apoE4 were kindly provided by Prof. Joachim Herz (University of Texas 
Southwestern Medical Center, USA). 
3.1.4. Buffer solutions and cell culture media 
Table 3.6: List of buffer solutions and cell culture media. 
Buffer Solution Composition 
Enzyme solution 
2 mg Cystein 
1 mM CaCl2 
0.5 mM EDTA, pH = 8 
in DMEM  




5 % FBS (Gibco, 10270106),  
1% penicillin/streptomycin (Gibco, 15150122) 
2.5 mg/ml albumin ( Sigma-Aldrich, A9418) 
2.5 mg/ml trypsin inhibitor ( Sigma-Aldrich, T9253) 
in DMEM 
Neuronal Plating Media  
2% B-27 (Gibco, 17504044) 
1% GlutaMAX (Gibco, 35050061) 
1% penicillin/streptomycin (Gibco, 15150122) 
in Neurobasal (Gibco, 21103049) 
DMEM complete medium 
10% FBS  
1% penicillin/streptomycin (P/S) 
in DMEM 
IP lysis buffer 
10 mM Tris/Cl pH 7.5; 
150 mM NaCl;  
0.5 mM EDTA;  
0.5% NP-40 
in water 
IP dilution/wash buffer 
10 mM Tris/Cl pH 7.5 
150 mM NaCl 
0.5 mM EDTA 
0.1% triton-100 
in water 




50 mM Tris-HCl pH 7.4 
150 mM NaCl 
0.1% SDS 




50 mMTris HCL, pH 7.4 
140 mM NaCl  
1% Triton X-100 
in water 
Base solution 
25 mM NaOH 
0.2 mM EDTA 
in water 
Neutralization solution 
40 mM Tris-HCl 
in water 
Wash Buffer/dialysis buffer 
5 mM tris-HCl pH 7.4 




5 mM tris-HCl pH 7.4 
1 M NaCl 
in water 
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30% ethylene glycol 
0.02 M phosphate buffer pH 7.4 
in water 









3.2. in vivo and ex vivo experiments 
The generation of mice lacking sortilin (Jansen et al. 2007) and Apoe targeted 
replacement (Knouff et al. 1999) strains of mice has been described. All lines were 
backcrossed to C57Bl6/J mice for at least seven generations. Animals were 
routinely genotyped by PCR and qRT-PCR using the primers listed in the Chapter 
3.1.1. and the genotyping procedures are described in Chapter 3.5.1. All animal 
experiments were approved by local ethics committees (LAGESO, Berlin, 
Germany). Animals were housed in the facility with the controlled environmental 
parameters under a 12 h light/12 h dark cycle. Mice were fed with standard chow 
(4.5% crude fat, 39% carbohydrates). Only male mice were used in all 
experiments at 10-13 weeks old, unless stated otherwise. Mice were sacrificed by 
cervical dislocation. Cortical brain area was rapidly dissected and frozen using dry 
ice. The tissues were stored at -80°C till further processing. 
3.2.1. Neurogenesis 
Bromodeoxyuridine (BrdU) is a thymidine analog that incorporates into dividing 
cells during DNA synthesis. BrdU labelling is the most used technique for studying 
adult neurogenesis in situ because of its ability to monitoring cell proliferation. 
Adult neurogenesis resides in two main locations in the adult brain, the 
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subventricular zone (SVZ) lining the lateral ventricles, and the hippocampal 
dentate gyrus (DG). 
BrdU (Sigma-Aldrich, B5002) was injected intra-peritoneally (i.p.) at a 
concentration of 50 mg/kg body weight. A 10 mg/ml stock solution of BrdU was 
prepared in sterile normal saline (0.9% NaCl) by sonication for 10 minutes 
followed by shaking at 300 rpm for 45 minutes at room temperature in the dark. 
Mice were anesthetized via i. p. administration of Ketamine/Xylazine. The dose of 
the drugs used: Ketamine (KetavetⓇ, Zoetis) 150 mg/kg body weight, Xylazine 
(RompunⓇ, Bayer) 20 mg/kg body weight. Mice in the surgical plane of anesthesia 
were transcardially perfused with PBS and then with 4% paraformaldehyde (w/v) 
in PBS. Brains were dissected and postfixed with the same fixative overnight at 
4°C. Brains were further rinsed in PBS and transferred in 30% sucrose (w/v) in 
PBS. After being equilibrated in the sucrose solution, brains were frozen and 
sectioned (40 μm coronally) on a sliding microtome SM2000R (Leica Biosystems). 
Brain free-floating sections were stored at -20°C in a cryoprotectant solution 
(composition in Table 3.6). 
After an extensive washing in TBS-T (Tris-buffered saline with 0.1% Triton X-100), 
the sections were treated with 6% H2O2 in TBS for 30 min at RT to quench the 
endogenous peroxidase. To allow the anti-BrdU antibody access to the BrdU 
within the DNA, the sections needed a DNA hydrolysis step where they were 
treated with 2 N HCl for 45 min at 40°C followed by 0,1 M borate buffer, pH 8.5 for 
10 min at room temperature. Then, the sections were blocked for one hour at room 
temperature (RT) in blocking solution. Thereafter, the sections were incubated with 
rat anti-BrdU overnight at 4°C in blocking solution. After being washed in TBS-T 
(3x), the sections were incubated with donkey anti-rat biotin SP (Jackson 
ImmunoResearch, 712-065-153) for two hours at RT. The VECTASTAIN® ABC 
Kit  (Vector Laboratories) is widely accepted as one of the most sensitive, 
economical and reliable immunoperoxidase detection systems available to detect 
any molecule that is biotinylated. The kit is composed by two paired reagents: 
Reagent A (Avidin DH, an avidin that is modified using a proprietary process to 
eliminate non-specific binding) and Reagent B (biotinylated peroxidase H with 
enhanced enzyme activity). Thus, the sections were incubated one hour at RT with 
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VECTASTAIN® ABC Reagents and then for 5 minutes at RT with the peroxidase 
substrate solution. In this case DAB (3,3′-Diaminobenzidine) (Sigma-Aldrich, 
D5905) was used. DAB is a derivative of benzene oxidized by hydrogen peroxide 
in a reaction catalyzed by peroxidase. DAB substrate solution was prepared in 
TBS with fresh 30% hydrogen peroxide and 8% of NiCl (metal enhancer). The 
reaction was stopped with tap water (3x) and then the sections were washed in 
TBS (3x), and finally mounted onto glass slides using RotiⓇ-Histokitt II mounting 
medium. 
Bright field microscopy (Leica DMI6000B inverted microscope) was used for image 
acquisition of subventricular zone (SVZ) and hippocampal dentate gyrus (DG) of 
the mouse brain models. Finally, BrdU-positive cells were counted using the 
ImageJ plugin ITCN. 
3.2.2. Golgi staining 
Morphological alterations in neuronal dendrites and dendritic spines can be 
studied using the Golgi technique. FD Rapid Golgistain Kit (FD 
NeuroTechnologies) has not only dramatically improved and simplified the Golgi 
technique but has also proven to be extremely reliable and sensitive for 
demonstrating morphological details of neurons. 
Mice were anesthetized via i. p. administration of Ketamine/Xylazine. Then, they 
were transcardially perfused with PBS. For the tissue preparation, brains were 
removed from the skull as quickly possible, rinsed with distilled water and then 
incubated with indicated solutions according to the manufacturer’s 
recommendations (FD Rapid Golgistain Kit, FD NeuroTechnologies). Sections 
(200 µm thickness) were cut on a vibratome with the chamber temperature set at -
22°C. Each section was mounted on gelatin-coated slides with a specific kit 
solution. After absorption of excess solution left on slide with a strip of filter paper, 
sections were naturally dried at room temperature for three days in the dark. For 
the staining procedure, sections were treated according to the manufacturer’s 
recommendations (FD Rapid Golgistain Kit, FD NeuroTechnologies) and finally 
mounted using Permount™ Mounting Medium.  
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Bright field microscopy (Leica DMI6000B inverted microscope) was used for image 
acquisition of pyramidal neurons in cortical layers II/III. Subsequently, the Fiji 
plugin “simple neurite tracer” was used to trace the dendrites of Golgi-stained 
pyramidal neurons and quantified the number and length of apical and basal 
dendrites, as well a quantitative assessment of neuronal complexity using an 
additional Fiji plugin called “Sholl analysis”. 
3.2.3. PPARs target genes assay 
The Mouse PPAR Targets RT² Profiler PCR Array (Qiagen) enables quick and 
reliable gene expression analysis of 84 key genes involved in peroxisome 
proliferator-activated receptor (PPAR) activation and response.  
Total RNA was extracted from mouse cortical tissues using the TRIzol reagent 
(Thermo Scientific, 15596026). Chloroform was added to the homogenates at the 
ratio 1:5 (v/v). The mixture was subjected to centrifugation at 12000 x g, 4°C for 10 
min. The upper, aqueous phase containing RNA was taken and gently mixed with 
70% ethanol at the ratio 1:1 (v/v). The resulting solution was applied to silica-
membrane column of RNeasy Mini Kit (Qiagen). RNA concentrations were 
determined using the NanoDrop ND-1000 spectrophotometer. Equal amounts of 
purified RNA, 1 μg, were used for complementary DNA (cDNA) synthesis using 
RT2 First Strand Kit (Qiagen). 
RT-PCR measurement of PPAR target genes was performed in combination with 
RT2 SYBR Green ROX qPCR Mastermix (Qiagen) using the 7900 HT Fast Real 
time PCR System (ThermoFisher) according to the manufacturer’s 
recommendations (PPAR Targets RT2 Profiler PCR Array, Qiagen). The target 
genes analysis was performed using Data Analysis Webportal (Qiagen) which 
ensures that each sample has passed the PCR Array Reproducibility, RT (reverse 
transcription) Efficiency, and Genomic DNA Contamination quality controls. 
Finally, the Ct values were extracted and the comparison in transcript levels of 
different genes was calculated using the cycle threshold (Ct) comparative method 
(2−ddCT) normalizing to Ct values of internal control gene Actb. 
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3.2.2. Primary culture 
Primary cortical neurons were isolated from newborn mice (postnatal day 0). 
Animals were sacrificed by decapitation. Cortices were rapidly dissected in cold 
HBSS containing Ca2+ and Mg2+ (Lonza, BE10-527F) and subjected to the 
digestion with papain (Sigma-Aldrich P3125) in enzyme solution for 1h at 37°C by 
vigorous shaking. 20-25 units of papain in 1 ml of the enzyme solution 
(composition in Table 3.6)  were used for the digestion of one half of cortex. The 
digestion was stopped by replacing the enzyme solution with stop solution 
(composition in Table 3.6)  for 5 min at 37°C under vigorous shaking. Afterwards, 
the tissue was washed (2x) in Neurobasal plating medium. Finally, the tissue was 
gently resuspended in the same medium using a pipette, and plated in 6-well 
plates coated with poly-D-lysine (Corning 356413) at a density of 40-60,000 
cells/cm. Neurons were cultured for 10-12 days in vitro before being used for 
western blotting or qRT-PCR. The medium was not changed during the culture 
period. 
Primary astrocyte cultures were prepared from newborn mice (postnatal day 0-1). 
Brains were rapidly dissected in cold HBSS and subjected to the digestion using 
mechanical dissociation (plastic Pasteur pipette and pipette tips) after enzymatic 
digestion with trypsin (Biochrom, # L2103-20) and DNAse (Worthington, #LS 
002139). Afterwards, the tissues were washed (2x) DMEM complete medium and 
plated on poly-L-lysine (Sigma-Aldrich, #P1274) coated T75 flasks and maintained 
in DMEM complete medium. After two days, the cultures were vigorous washed 
with PBS prior to medium change. Cells were cultured for 4 more days before 
samples were collected for Western blot and qRT-PCR analyses. 
3.3. in vitro experiments 
Chinese hamster ovary (CHO-K1) cells and HEK293 were grown on 10 cm culture 
dishes at 37°C, 5% CO2 in a 95% humidified environment in DMEM complete 
medium. Cells were subcultured at 1:6-1:12 ratio upon reaching confluency. For 
splitting, cells were detached from the culture dish surface using 0.05% 
trypsin/EDTA (Gibco 25300054). Transient transfections were performed using 
LipofectaminⓇ 2000 (Invitrogen) according to manufacturer’s recommendations.  
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CHO stably cell line were generated by transfecting either mouse sortilin and myc-
tagged mouse FABP7 (Origene, MR200772) (CHO-S/F or CHO-S) expression 
plasmids and by selecting transfected cells with puromyicin (10 µg/ml, Gibco, 
A11138-03) for sortilin and G418 (500 µg/ml, Gibco, 10131-027) for FABP7 until 
all non-transfected cells had died. Single cell colonies were picked, expanded, and 
tested for sortilin or sortilin/FABP7 expression by immunofluorescence staining 
and Western Blot. Stable cell lines were cultured in the presence of the respective 
antibiotic. 
3.3.1. Co-immunoprecipitation (Co-IP) 
For co-IP experiment, myc-tagged proteins were isolated by immunoprecipitation 
using the Myc-Trap® that utilizes small recombinant antibody fragments covalently 
coupled to the surface of magnetic agarose beads. In detail, CHO cells stable 
expressing FABP7 and sortilin were growth until confluence and then lysed in the 
IP lysis buffer containing protease Inhibitor cOmplete cocktail (Roche, 
04693116001). The lysates were cleared by centrifugation at 12000 x rpm, 4°C for 
10 minutes. Protein concentration was determined using BCA protein Assay Kit 
(Thermo Fisher, 23225). 300 µg of the lysates were diluted in IP dilution buffer and 
pre-cleared with control beads (Chromotek, bmab-20) for 15 minutes at 4°C under 
continuous rotation. Then the lysate were incubated with Myc-Trap Magnetic 
Agarose (Chromotek, ytma-20) for one hour at 4°C under continuous rotation. 
Antibody/protein complexes were isolated from the lysates using a magnetic rack 
and washed (3x) with IP wash buffer. Proteins were eluted by incubating the 
magnetic beads in 2x Laemmli buffer (Sigma-Aldrich, S3401-10VL) for 10 min at 
95°C. Proteins were resolved on polyacrylamide gels and analyzed by Western 
blotting. 
3.3.2. Proximity ligation assay (PLA) and co-localization studies 
Proximity ligation assay (PLA) is a powerful tool to test protein interactions with 
high specificity and sensitivity in cells. Protein targets can be readily detected and 
localized with single molecule resolution and objectively quantified in unmodified 
cells. Typically, It employs two primary antibodies raised in different species that 
detect two proteins of interest. Then, if both oligonucleotide-conjugated secondary 
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antibodies (PLA probes) are in close proximity, this allows for their hybridization by 
connector oligonucleotides, forming a circular DNA strand that can be amplified by 
PCR (amplification step). The DNA synthesis reaction results in several-
hundredfold amplification of the DNA circle. Incorporation of fluorescence-labelled 
oligonucleotides in the PCR product enables localized detection of protein 
interaction.  
Here, Chinese hamster ovary (CHO-K1) cells stably overexpressing mouse sortilin 
and myc-tagged mouse FABP7 were grown on glass coverslips coated with 0.1 % 
gelatin (from porcine skin) in DPBS for 1 hour at room temperature prior to use. 
Gelatin was aspirated and dish quickly washed with 1X DPBS before plating. Upon 
70% confluency, the cells were treated for 24 hours with conditioned medium 
containing 5 µg/ml of human apoE3 and apoE4. Cells were then fixed in 4% PFA 
for 10 minutes at room temperature, washed with DPBS (3X, 10 minutes) and 
stored at 4°C in DPBS for no longer than 2 weeks. Cells were permeabilized with 
0.3% triton/PBS for 15min RT. Then, the cells were blocked, incubated with 
primary antibodies and subjected to proximity ligation assay (PLA) using Far-Red 
PLA probes, followed by ligation and amplification performed according to the 
manufacturer’s recommendation (Sigma-Aldrich). 
To determine the degree of co-localization between FABP7-Sortilin (PLA signals) 
with endosomal markers, after the PLA amplification step, the cells were incubated 
with primary and secondary antibodies to co-stain the cells for the indicated 
marker proteins. Antibodies used were anti-Rab5 (Cell Signaling, #2143, 1:500), 
anti-Rab11 (Cell Signaling, #5589, 1:500), as well as Alexa Fluor 647-conjugated 
secondary antibody. Finally, the cells were counterstained with DAPI and mounted 
in DAKO fluorescence mounting medium.  
For Confocal images of immunofluorescent stained cells, a Leica SPE laser-
scanning microscope was used at the MDC imaging core facility. Images were 
acquired using the Leica LAS AF Lite software. Microscopy images were 
quantified using Fiji software. Colocalization analysis was performed with the 
Colocalization Threshold plugin with manual selection of the region of interest 
(ROI). Single z-plane images were used for calculating Mander’s coefficient (tM) 
that is proportional to the fluorescence intensity of the colocalizing pixels in each 
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channel with tM=0 representing no colocalization and tM=1 representing perfect 
colocalization (MANDERS et al. 1993). 
3.3.3. Protein stability by the cycloheximide chase assay  
Protein stability of FABP7 in CHO cells has been achieved by cycloheximide 
(CHX) (Sigma-Aldrich, C7698), an antibiotic produced by the bacterium 
Streptomyces griseus. CHX is an inhibitor of protein biosynthesis due to its 
prevention in translational elongation. It is broadly used in cell biology in terms of 
determining the half-life of a given protein without confounding contributions from 
transcription or translation.  
In details, cells expressing (CHO-S) or lacking sortilin (CHO) were seeded in 6-
well plates and transiently transfected with a FABP7 expression construct. 48 
hours post transfection, replicate cultures of transfected cells were treated with 10 
µg/ml of cycloheximide in DMEM complete medium and collected at time points 0, 
4, 8, and 12 hours later. Confluent 6-wells were lysed in lysis buffer containing 
proteinase inhibitors for 30 minutes at 4 °C. Cell debris was removed by 
centrifugation for 10 min at 12,000 x rpm at 4 °C and the supernatant was 
transferred to a new tube. Protein lysates were analyzed by Western Blot and 
levels of FABP7 were quantified using the Image Studio Lite software and 
normalized to the loading control protein GAPDH. 
3.3.4. APOE production  
HEK 293 cells were plated in 10 cm dishes and transiently transfected using 
Lipofectamine 2000 (ThermoFisher) according to manufacturer’s instructions with 
pcDNA3.1 zeo(+) human apoE3, or pcDNA3.1 zeo(+) human apoE4. APOE 
lipoproteins were naturally secreted from cells. Cell supernatants were conditioned 
for 48 hours in DMEM without FCS (Chen et al. 2010). Then, cells debris were 
removed by centrifugate the supernatant at 300g per 3 minutes. Finally, the 
concentration of APOE isoforms in the cell media was determined by western blot 
analysis comparing APOE signal intensities to those from serial dilutions of 
recombinant human APOE (MBL, JM-4699-500) included in the same blots. 
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3.4. Human studies 
3.4.1. Brain tissue 
Brain autopsy specimens from the frontal cortex of AD patients and control 
subjects were obtained from the Netherlands Brain Bank (Netherlands Institute for 
Neuroscience, Amsterdam) and the MRC London Brain Bank for 
Neurodegenerative Diseases (Institute of Psychiatry, King's College London). The 
ethnicity of samples was white. All material was collected from donors for or from 
whom a written informed consent for a brain autopsy and the use of the material 
and clinical information for research purposes had been obtained by the 
Netherlands Brain Bank or the MRC London Brain Bank. Detailed personal 
information, including age, gender, neuropathological stage, APOE genotypes, of 
the individuals were provided by the brain banks. Pieces of brain tissue were 
either lysates for western blotting or used for lipidomics analysis. 
3.4.2. CSF samples and APOE-containing particles isolation 
Cerebrospinal fluid (CSF) samples from AD patients and controls were obtained 
from a local biomaterial bank. The study was approved by an institutional review 
board (Ethikausschuss 2 Charité; BIH CRG 2a, EA2/118/15). Written informed 
consent was obtained from all individuals prior to participating in this study. 
Thus, human liquor and murine HDL samples were subjected to APOE affinity 
chromatography using HiTrap Heparin columns (GE Healthcare, 17-0406-01). 
First the samples were dialyzed using Slide-A-Lyzer Dialysis Cassette ( 
ThermoFisher, 66382) in wash/dialysis buffer (see Table 3.6) overnight at 4°C in 
agitation. Then according to the manufacturer's protocol HiTrap™Heparin HP 
Column was equilibrate with wash/dialysis buffer and the CSF samples were 
conveyed over the column. The flow-through (APOE-free particles) was collected, 
while APOE-containing particles stick to the column. Heparin-bound lipoproteins 
were eluted with elution buffer containing high concentration of salt and then 
concentrated using Amicon centrifugal filter units (Millipore, UFC801024) previous 
washed with 1 % albumin Fatty acids-Free in PBS. All CSF samples were stored 
at -80°C until further processing for lipidomics analyses. The enrichment of APOE 
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in the eluate fractions but not in the heparin column flow-through is documented by 
western blotting. 
3.5. Common and shared techniques  
Plasmid cDNA preparation and isolation form bacteria, SDS polyacrylamide gel 
electrophoresis and Western Blot were performed using standard procedures. Of 
note, mouse tissues lysates for immunoblotting were obtained by homogenization 
of tissues in RIPA buffer, instead mouse primary culture and in vitro cells with lysis 
buffer (see Table 3.6 for buffer solutions). The intensities of immunoreactive bands 
signals were quantified by densitometric scanning of blots using the Image Studio 
Lite software. 
3.5.1. Genotyping 
Genomic DNA for PCR or SNP genotyping was obtained from mouse ear or tail. 
Biopsied tissue was incubated for 30 min at 95°C in base solution, followed by 
addition of the equal volume of neutralization solution.  
Extracted DNA was used in PCR with the following cycling conditions: (1) initial 
denaturation (2 min, 94°C), (2) denaturation (15 sec, 94°C), (3) annealing (15 sec, 
57°C for sortilin) (4) elongation (30 sec, 72°C). Steps (2) to (4) were repeated 40 
times in total. Primers used for PCR are listed in Table 3.1. The composition of the 
reaction mixture was as follows: Taq DNA polymerase (NEB M0267; 0.03 U/μl), 1x 
ThermoPol Buffer, 0.2 mM of each deoxynucleotide triphosphates, 0.2 μl primers. 
PCR products were resolved on 2% agarose gels. Expected sizes of PCR 
products used for determination of mouse genotypes were for sortilin allele – 293 
bp (WT) and 206 bp (KO). 
APOE isoforms genotyping was performed using pre-designed TaqMan-based 
SNP genotyping assays (Thermo Fisher). These assays contain two allele-specific 
probes labelled either with FAM or VIC dye that specifically recognize the major or 
minor allele, respectively. Genomic DNA was diluted to a concentration of 1 ng/μl 
and 5 μl of the diluted DNA solution were pipetted into a 384-well-plate. A water 
sample was included as negative control. Covered with a dry paper tissue, wells 
were dried over night before adding the SNP genotyping probe-mastermix. PCR 
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amplification and fluorescent measurement of the wells was performed using 
QuantStudio 6 Flex Real-Time PCR-System (Thermo Fisher) SNP genotypes of all 
samples were assigned by the software based on FAM/VIC fluorescence ratios. 
3.5.2. Quantitative RT-PCR 
To extract total RNA from mouse tissues, they were first homogenized in TRIzol 
reagent (Thermo Scientific, 15596026). Chloroform was added to the 
homogenates at the ratio 1:5 (v/v). The mixture was subjected to centrifugation at 
12000 x g, 4°C for 10 min. The upper, aqueous phase containing RNA was taken 
and gently mixed with 70% ethanol at the ratio 1:1 (v/v). The resulting solution was 
applied to silica-membrane column of RNeasy Mini Kit (Qiagen).  
DNase treatment of the sample was performed directly on the purification column 
by addition of RNase-free DNase I (Qiagen) prepared according to manufacturer’s 
instructions and incubated for 15 min at room temperature after the first washing 
step. RNA concentrations were determined using the NanoDrop ND-1000 
spectrophotometer. Equal amounts of purified RNA, 50 ng to 1 μg, were used for 
complementary DNA (cDNA) synthesis using High Capacity RNA to cDNA Kit 
(Applied Biosystems).  
Samples were measured in triplicates using the 7900 HT Fast Real time PCR 
System (Thermo Fisher) using commercially available Taqman Gene Expression 
Assays or DNA oligonucleotides flanking the target region and SYBR green dye. 
TaqMan probes and DNA oligonucleotides are specified in Table 3.3 and Table 
3.4. The data were analysed using the cycle threshold (CT) comparative method 
(2−ddCT) normalizing to CT values of internal control gene. The Ct value of each 
sample represents the number of cycles needed for the emitted fluorescence 
signal to cross a defined threshold. The abundance of the target mRNA is 
therefore inversely correlated to the Ct value. The Ct value for a house keeping 
mRNA was subtracted from the Ct value for the mRNA of interest to ensure equal 
amount of cDNA in each well (dCt). For comparison of multiple samples, the dCt 
value of the internal control was subtracted from the dCt values of the other 
samples (ddCt) and data were presented as log2 change in expression.  
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In the case of SYBR green, the PCR specificity was verified performing the 
dissociation (melting) curve analysis. Post-amplification melting-curve analysis is a 
simple, straightforward way to check real-time PCR reactions for primer-dimer 
artefacts and to ensure reaction specificity. As the temperature steadily increases, 
the fluorescence will drop suddenly each time the temperature reaches the 
characteristic melting point (Tm) of a DNA fragment. Tm refers to the temperature 
at which 50% of DNA in a sample has denatured from double-stranded DNA 
(dsDNA) to single-stranded DNA (ssDNA). Pure, homogeneous PCR products 
produce a single, sharply defined melting curve with a narrow peak. In contrast, 
primer dimers melt at relatively low temperatures and have broader peaks. 
3.5.3. Lipid analysis 
Targeted lipidomics was performed on brain cortex specimens from human 
subjects or mice or on APOE-containing lipoproteins isolated from human 
cerebrospinal fluid by the company Lipidomix GmbH (Berlin, Germany) (as 
followed. 
For FA profiling, 30 mg of human or mouse brain cortex were hydrolyzed with 100 
µl 10 mol/l NaOH within 60 min at 80°C. The samples were neutralized with 100 µl 
acetic acid. An 50 µl aliquot was diluted 1:10 with methanol containing internal 
standards (50 µg of C15:0 and C21:0; 5 µg of C20:4-d8 and C18:2-d4, and 1 µg of 
C20:5-d5 and C22:6-d5; Cayman Chemical, Ann Arbor MI). HPLC measurements 
were performed using an Agilent 1290 HPLC system with binary pump, 
autosampler and column thermostat equipped with a Phenomenex Kinetex-C18 
column 2.6 µm, 2.1 x 150 mm column (Phenomenex, Aschaffenburg) using a 
solvent system of acetic formic acid (0.1%) and acetonitrile. The solvent gradient 
started at 70 % acetonitrile and was increased to 98 % within 10 min and kept until 
14 min with a flow rate of 0.4 ml/min and 5 µl injection volume. The HPLC was 
coupled with an Agilent 6470 triplequad mass spectrometer with electrospray 
ionisation source and operated in negative selected ion mode. 
For eCB profiling, 10 mg cortex tissue was homogenized in 300 µl distilled water. 
Then, 25 µl citric acid (0.4 mol/l), 10 µl of internal standards (10 µg/ml DHA-
Ethanolamid-D4, Anandamid-D4, EPA-Ethanolamid-D4; Cayman Chemical, Ann 
Arbor MI) and 1 ml ethyl acetate were added. The samples were shaken for 
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10 min, centrifuged for 3 min at 3500 rpm and the upper phase recovered. Next, 
1 ml ethyl acetate was added to the lower (sample) phase, followed by shaking for 
further 10 min and centrifugation for 3 min at 3500 rpm. Again, the upper phase 
was recovered and both supernatants combined. The solvent was removed to 
dryness at 40°C under a stream of N2, before the pellets were resuspended in 100 
µl acetonitrile and eCB measured. HPLC-measurement was performed using an 
Agilent 1290 HPLC system with binary pump, autosampler, and column thermostat 
equipped with a Phenomenex Kinetex-C18 column 2.6 µm, 2.1 x 150 mm column 
(Phenomenex, Aschaffenburg, DE) using a solvent system of formic acid (0.1 %) 
and methanol. The solvent gradient started at 5 % methanol and was increased to 
95 % within 10.6 min under gradient conditions and kept until 15 min with a flow 
rate of 0.7 ml/min and a 10 µl injection volume. The HPLC was coupled with an 
Agilent 6490 triplequad mass spectrometer with atmospheric pressure chemical 
ionization source operated in positive selected ion mode. 
3.5.4. Statistical analysis 
Statistical analysis was performed using the GraphPad Prism 7.0 software. Two 
experimental groups were compared using an unpaired Student’s t-test. For 
experiments, when testing for the influence of two independent variables, two-way 
ANOVA with Bonferroni multiple comparison post-test was used. P-values of less 
than 0.05 were considered statistically significant with * representing p<0.05, ** 
representing p<0.01, *** representing p<0.001, and **** representing p<0.0001. All 
quantitative data are shown as the mean ± standard error of the mean (SEM), if 
not otherwise stated. 
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4. RESULTS 
4.1. The fatty acid profile is altered in the brain of mice 
lacking sortilin and with apoE4 genotype 
Lipids are fundamental for the structural and functional integrity of the brain 
and APOE, the most abundant apolipoprotein in the central nervous system, 
represents the major carrier of cholesterol and phospholipids to neurons 
(Holtzman and Herz 2012). Thus, alteration of brain lipid homeostasis may explain 
the Alzheimer’s disease (AD) risk associated with the apoE4 variant in humans. 
However, this area of research has been understudied as the amyloid and tau 
hypotheses have dominated the field of AD research for many years. Previously, 
Dr. Anne-Sophie Carlo in the Willnow laboratory found that sortilin controls murine 
lipoprotein metabolism by acting as a neuronal receptor for APOE. Moreover, loss 
of sortilin results in an increase in brain lipid sulfatides (Carlo et al. 2013). 
Consequently, in order to elucidate the relevance of sortilin for APOE-dependent 
brain lipid homeostasis and to explain the risk of AD associated with the human 
apoE4 but not the apoE3 variant, lipidomics analyses were performed in mice 
either wild-type (WT) or homozygous for the Sort1 null allele (KO) and expressing 
the human variants apoE3 (E3) or apoE4 (E4). More precisely, the murine Apoe 
gene locus in these mice was replaced with genes encoding the human isoforms 
E3 or E4 (Knouff et al. 1999). These two lines were crossed with mice either wild-
type or genetically deficient for sortilin (Jansen et al. 2007). 
In the brain, fatty acids (FA) are enriched, predominantly esterified to other lipids 
(total FA) such as cholesterol and phospholipids. Due their multitude of functions 
as signaling molecules, brain FA receive more and more attention in 
neuroscience. In collaboration with the company Lipidomix (Campus Berlin-Buch), 
cortices of my four mouse strains were isolated and subjected to liquid 
chromatography-mass spectrometry (LC-MS) to establish total cholesterol and 
fatty acid profiles. While the total cholesterol profile was unaltered (Figure 4.1A) 
comparing genotypes, the pool of total fatty acids was decreased in (E4;WT), 
(E4;KO) and (E3;KO) mice compared to (E3;WT) animals. Of note, no alteration in 






Figure 4.1: Total FA in murine brain cortex are altered by sortilin and E4 genotype. 
(A) Levels of total cholesterol and (B) total fatty acids (FA) were quantified by liquid 
chromatography-mass spectrometry (LC-MS) in brain cortices of apoE3 and apoE4-targeted 
replacement mice at 3 months of age. The mice were either WT or KO for sortilin (E3;WT, E3;KO, 
E4;WT or E4;KO). Data are shown as mean ± SEM. n=6-12 animals per genotype. The 
significance of data was determined by Two-way ANOVA followed by Bonferroni post-hoc analysis 
(*, p<0.05; ***, p<0.001). 
Fatty acids can be classified as saturated or unsaturated depending on the 
absence or presence of double bonds in their carbon chain. FA that have more 
than one carbon-carbon double bond are called polyunsaturated fatty acids 
(PUFA), while FA with only one carbon-carbon double bond are referred as 
monounsaturated FA. Moreover, unsaturated FA can be further classified 
depending on the position of carbon-carbon double bonds along the carboxylic 
acid chain (omega, ω; n-) (Fahy et al. 2005). To better understand which lipids 
were altered in the pool of FA measured above, in-depth analysis of mouse brain 
cortices according to FA lipid classes was performed. From this analysis, no 
obvious alterations in saturated and monounsaturated lipids were observed 
(Figure 4.2). 
Further analysis of omega-6 and omega-3 unsaturated FA, the two most 
prominent and important PUFA present in the brain, revealed neither a change in 
arachidonic acid (ARA) (Figure 4.3A) nor in other members of the omega-6 PUFA 
class. Of note, an effect of the APOE allele was seen for linoleic acid, osbond acid 









(A) Saturated and (B) monounsaturated fatty acids were quantified by liquid chromatography-mass 
spectrometry (LC-MS) in brain cortices of E3 and E4-targeted replacement mice at 3 months of 
age. Mice were either WT or KO for sortilin (E3;WT, E3;KO, E4;WT or E4;KO). Data are shown as 
mean ± SEM. n=12 animals per genotype. The significance of data was determined by Two-way 
ANOVA followed by Bonferroni post-hoc analysis (*, p<0.05; **, p<0.01). 
 




(A) Levels of arachidonic acid (ARA) and (B) other unsaturated omega-6 lipids were quantified by 
liquid chromatography-mass spectrometry (LC-MS) in brain cortices of E3 and E4-targeted 
replacement mice at 3 months of age, either WT or KO for sortilin (E3;WT, E3;KO, E4;WT or 
E4;KO). Data are shown as mean ± SEM. n=12 per genotype. The significance of data was 
determined by Two-way ANOVA followed by Bonferroni post-hoc analysis (*, p<0.05). 
However, a change was observed in the omega-3 PUFA docosahexaenoic acid 
(DHA) with levels being decreased in (E4;WT), (E4;KO), and (E3;KO) animals 
compared to (E3;WT) mice.  
 
Figure 4.4: Docosahexaenoic acid levels in the murine brain are altered by sortilin and 
apoE4 genotype. 
(A) Levels of docosahexaenoic acid (DHA) and (B) other omega-3 PUFA were quantified by liquid 




replacement mice at 3 months of age, either WT or KO for sortilin (E3;WT, E3;KO, E4;WT or 
E4;KO).  Data are shown as mean ± SEM. n=12 animals per genotype. The significance of data 
was determined by Two-way ANOVA followed by Bonferroni post-hoc analysis (*, p<0.05; **, 
p<0.01; ***, p<0.001). 
As seen for total FA before, the presence or absence of sortilin did not affect DHA 
levels in E4 mice (Figure 4.4A). While most members of the omega-3 lipid class 
were not altered, an effect of the APOE allele was however seen for linolenic acid 
(Figure 4.4B). 
4.2. The DHA-based metabolite synaptamide is altered by 
sortilin and apoE4 genotype 
DHA is one of the most extensively studied lipids in the brain. The continued 
interest in this lipid may be explained by its significant neuroprotective impact. 
Indeed, several studies have demonstrated that DHA has a positive impact during 
aging and in neurodegenerative diseases, such as AD (Echeverría et al. 2017). 
However, DHA is not acting alone as several of its beneficial effects are mediated 
by metabolites derived from enzymatic modification of DHA. In detail, DHA can be 
processed by a number of different enzymes such as lipoxygenase (LOX), 
cytochrome P450 (CYP), or N-acyl phosphatidylethanolamine-specific 
phospholipase D (NAPE-PLD) into hydroxy-docosahexaenoic acid (HDHA), 
epoxy-docosapentaenoic acid (EDP), or dihydroxy-docosahexaenoic acid 
(DiHDHA) and N-docosahexaenoylethanolamine (synaptamide), respectively 
(Figure 4.5A).  These DHA-derived bioactive lipids have pleiotropic roles in the 
brain that include the regulation of inflammation, synaptic plasticity, and aging 
(Kuda 2018). No alterations in HDHA and DiHDHA levels were observed in the 
brains of mice expressing E3 or E4. However, an increase of EDP lipids were 
detected in the brain cortex of (E4;WT) and (E4;KO) compared to the respective 
(E3;WT) and (E3;KO) mice (Table 4.1). By contrast, synaptamide was decreased 
in (E4;WT), (E4;KO), and (E3;KO) mice compared with (E3;WT) animals. As seen 
for the total FA and DHA before, the presence or absence of sortilin did not affect 
synaptamide levels in E4 mice (Figure 4.5B). Although yet poorly studied, early 
work showed that synaptamide is structurally similar to the endocannabinoid (eCB) 




eCB-like lipid. eCBs are well-known PUFA-derived metabolites that control 
neuroprotective and pro-neurogenic processes.  With relevance to my studies, 
eCBs have shown therapeutic potential in brain ageing and neurodegenerative 
conditions (Benito et al. 2007). Hence, further lipidomics analyses was performed 
to study if eCBs other than synaptamide were also altered in the mouse brain in 
response to sortilin and APOE genotypes. 
 
Figure 4.5: Synaptamide levels are affected by sortilin and E4 genotype. 
(A) Pathways to produce DHA-based metabolites. (B) Synaptamide levels were quantified by liquid 
chromatography-mass spectrometry (LC-MS) in brain cortices of E3 and E4-targeted replacement 
mice at 3 months of age, either WT or KO for sortilin (E3;WT, E3;KO, E4;WT or E4;KO). Data are 




Two-way ANOVA followed by Bonferroni post-hoc analysis (*, p<0.05; ***, p<0.001; ****, 
p<0.0001). 
Lipid Name Enzyme 2way ANOVA 
7,8-EDP  CYP *  For APOE 
10,11-EDP  CYP *  For APOE 
13,14-EDP  CYP *  For APOE 
16,17-EDP  CYP *  For APOE 
19,20-EDP  CYP *  For APOE 
7,8-DiHDPA  CYP ns 
10,11-DiHDPA  CYP ns 
13,14-DiHDPA  CYP ns 
16,17-DiHDPA  CYP ns 
19,20-DiHDPA  CYP ns 
4-HDHA  LOX ns 
7-HDHA  LOX ns 
8-HDHA  LOX ns 
10-HDHA  LOX ns 
11-HDHA  LOX ns 
13-HDHA  LOX ns 
14-HDHA  LOX ns 
16-HDHA  LOX ns 
17-HDHA  LOX ns 
20-HDHA  LOX ns 
21-HDHA  LOX ns 
22-HDHA  LOX * For sortilin 
 




Epoxy-docosapentaenoic acid (EDP), dihydroxy-docosahexaenoic acid (DiHDHA), and hydroxy-
docosahexaenoic acid (HDHA) were quantified by liquid chromatography-mass spectrometry (LC-
MS) in brain cortices of E3 and E4-targeted replacement mice at 3 months of age, either WT or KO 
for sortilin (E3;WT, E3;KO, E4;WT or E4;KO). n=9-12 animals per genotype. The significance of 
data was determined by Two-way ANOVA followed by Bonferroni post-hoc analysis (*, p<0.05). 
No alterations in the levels of the synaptamide analogue anadamide (AEA) or of 
linoleoyl-ethanolamide (LEA) were found (Figure 4.6A). By contrast, levels of 2-
arachidoylglycerol (2-AG) were increased in (E4;WT), (E4;KO), and (E3;KO) mice 
compared to (E3;WT) animals (Figure 4.6B). Conversely, levels of palmitoyl-
ethanolamide (PEA) and oleyl-ethanolamide (OEA) were decreased in (E3;KO) 
and (E4;KO) mice compared to the corresponding sortilin WT mice (Figure 4.6C). 
 




(A) Levels of anadamide (AEA) and linoleoyl-ethanolamide (LEA), as well as (B) 2-
arachidoylglycerol (2-AG), and (C) palmitoyl-ethanolamide (PEA) and oleyl-ethanolamide (OEA) 
lipids were quantified by liquid chromatography-mass spectrometry (LC-MS) in brain cortices of E3 
and E4-targeted replacement mice at 3 months of age, either WT or KO for sortilin (E3;WT, E3;KO, 
E4;WT or E4;KO).  Data are shown as mean ± SEM. n=12 animals per genotype. The significance 
of data was determined by Two-way ANOVA followed by Bonferroni post-hoc analysis (*, p<0.05; 
***, p<0.001; ****, p<0.0001). 
As in the murine brain, I also observed alterations in PUFA and eCB homeostasis 
in the brains of patients suffering from AD. Lipidomics analyses of frontal cortex 
specimens of AD patients showed changes reflecting the observed alterations in 
mice. Thus, the levels of synaptamide were significantly decreased in APOE4/4 
compared with APOE3/3 carriers.  
 




Levels of synaptamide and AEA (A), and of LEA, PEA, OEA, and 2-AG (B) were quantified by 
liquid chromatography-mass spectrometry (LC-MS) in prefrontal cortex specimens of AD patients 
either APOE3/3 or APOE4/4 (n=10 for APOE4/4, n=34 for APOE3/3). Values are mean ± SEM. 
The significance of data was determined by Student’s t-test (*, p<0.05). 
Moreover, the levels of AEA were also decreased in APOE4/4 vs. APOE3/3 
patients (Figure 4-7A), whereas the levels of 2-AG, OEA, LEA, and PEA were 
unaltered (Figure 4.7B). In accordance with findings in mice, levels of 2-AG were 
increased in APOE4/4 compared to APOE3/3 carriers with a p value that almost 
reached significance (p=0.057). 
4.3. Neurogenesis and neuroplasticity are not affected by 
sortilin and APOE genotypes 
It is now well-established that after birth new neurons are generated from neuronal 
stem cells (NCS) in the mammalian brain. Adult neurogenesis proceeds in two 
regions of the mammalian brain, namely the subgranular layer of the hippocampal 
dentate gyrus (DG) and the subventricular zone (SVZ) of the lateral ventricles. 
Adult neurogenesis plays an important role in learning and memory through the 
regulation of synaptic plasticity and ageing (Bartsch and Wulff 2015). Several 
lipids, including PUFA and eCBs, have been reported to affect adult neurogenesis. 
For example, adult rats fed DHA show an increase in neurogenesis in the 
hippocampi, due to enhancement of neuronal proliferation and suppression of cell 
death (Kawakita et al. 2006). Synaptamide was found to induce neuronal 
differentiation of NCS at concentrations even lower than those required from DHA 
(Rashid et al. 2013). Finally, inhibition of diacylglycerol lipases (DAGL), the 
enzyme important for 2-AG synthesis, suppresses neuronal proliferation in adult 
mice (Goncalves et al. 2008). Given the changes of PUFA and eCBs in mice 
deficient for sortilin, I next analyzed adult neurogenesis in the brains of the 
respective mouse models. The commonly used methods to query adult 
neurogenesis in vivo is the application of 5’-bromo-2’-deoxyuridine (BrdU). BrdU is 
a thymidine analogue incorporated into replicating DNA of proliferating cells. It’s 
retained in the genome in subsequent cell divisions and can be detected using 
specific antibodies. To study adult neurogenesis in my mouse models, I injected 




brains were subjected to immunohistological detection of BrdU-positive cells in the 
hippocampal DG (Figure 4.8A). In the DG of 3 month old mice, the presence or 
absence of sortilin did not impact the extent of adult neurogenesis as no change in 
the number of BrdU-positive cells was seen in (E3;KO) compared to (E3;WT) mice 
(Figure 4.8B). 
In rodents, adult neurogenesis is essential for olfaction as neural progenitor cells 
generated in the SVZ migrate along the rostral migratory stream to form distinct 
subtypes of neurons in the olfactory bulbs (Carleton et al. 2003).  
 
Figure 4.8: Adult neurogenesis in the dentate gyrus (DG) of E3 mice is not impacted by 
sortilin deficiency. 
(A) Immunohistochemical detection of BrdU-positive cells in the hippocampal DG of (E3;WT) and 




of the total number of BrdU-positive cells in the hippocampal DG.  Three to five coronal sections 
(40 µm) from each animal were used for analysis. (n=3 animals per genotype). Values are mean ± 
SEM. 
Like in the stem cell niche of the DG, SVZ neurogenesis was also not affected by 
sortilin deficiency in E3 mice as the numbers of BrdU-positive cells were 
unchanged comparing (E3;WT) and (E3;KO) mice (Figure 4.9). 
 
Figure 4.9: SVZ neurogenesis is not affected by sortilin in E3 mice. 
(A) Immunodetection of BrdU-positive cells in the SVZ of (E3;WT) and (E3;KO) mice at 3 months 
old injected with BrdU for 24 hours. Scale bar: 100 μm. (B) Quantification of the total number of 
BrdU-positive cells in (E3;WT) and (E3;KO) mice.  Two to four coronal sections (40 µm) per animal 




It has also been shown that PUFA promote dendritic arborization in primary 
neuronal cultures (Latifi et al. 2016). During adult life, the dynamic morphological 
changes of neuronal dendrites, called neuroplasticity, are tightly correlated with 
the functional integrity of the brain. Along these lines, the major risk factor of 
Alzheimer’s disease, apoE4, decreases the dendritic complexity in mouse cortical 
neurons (Dumanis et al. 2009). Alteration of lipid homeostasis may impact the 
neuronal morphology, for this purpose, a commercial kit based on Golgi staining 
method was employed. The technique is named after his developer Camillo Golgi 
and uses silver nitrate impregnation that allows the visualization of neuronal cell 
soma, axons, dendrites and spines. Golgi's method stains randomly a limited 
number of cells, however the mechanism by which this happens is still largely 
unknown (Kang et al. 2017). 





(A) Representative image of Golgi-impregnated pyramidal neurons in cortical layers II/III of 
(E3;WT), (E3;KO), (E4;WT) and (E4;KO) mice at 3 months of age. Scale bar: 50 μm. (B) Sholl 
analysis of neurons in cortical brain sections of (E3;WT), (E3;KO), (E4;WT) and (E4;KO) mice at 3 
months of age. (n=3-4 animals per genotype, 7 neurons per mouse analysed). Values are mean ± 
SEM. 
To test the effect of sortilin and APOE isoforms on the dendritic complexity and 
arborization of pyramidal neurons in cortical layers II/III, mouse brains were 
dissected, sectioned and stained using the Golgi staining method for neurons 
(Figure 4.10A). Subsequently, the Fiji plugin “simple neurite tracer” was used to 
trace the dendrites of Golgi-stained pyramidal neurons. This tool allows for the 
quantitative assessment of neuronal complexity using an additional Fiji plujin 
called “Sholl analysis” that creates a series of concentric shells around the 
neuron’s soma and quantifies the number of dendritic intersections per shell that 
occur at fixed distances from the soma. As shown in Fig. 4.10B, the Sholl profile of 
neurons was similar in all genotype groups. Also, using the Fiji plugin “simple 
neurite tracer” tool, no impact of sortilin and APOE isoforms on the numbers 
(Figure 4.11A) or the length (Figure 4.11B) of apical and basal dendrites in the 
various mouse strains was noted. 
 




(A) Branch number for apical and basal dendrites and (B) length of apical and basal dendrites (in 
µm) in (E3;WT), (E3;KO), (E4;WT) and (E4;KO)  at 3 month old mice. (n=3-4 animals per 
genotype, 7 neurons per mouse). Values are mean ± SEM. 
4.4. PPARs pathway is altered in the brain of mice lacking 
sortilin and with apoE4 genotype 
Alteration of PUFA and eCBs levels seen in E4 mice or in E3 animals lacking 
sortilin did not coincide with defects in adult neurogenesis or neuroplasticity in 
brain of the respective mouse strains. To investigate other possible consequences 
of altered levels of PUFA and eCBs for functional integrity of the mouse brain, I 
next focused on the activity of peroxisome proliferator-activated receptors 
(PPARs). PPARs are a class of ligand-induced nuclear receptors that are 
activated by PUFA to control target gene transcription. For this reason, I 
investigated the effect of the alteration in DHA and eCB levels on PPAR activities 
in my mouse models. Specifically, I used an unbiased systemic approach of a 
PCR profiler assay from Qiagen to quantify the transcript levels of 84 PPAR target 
genes in the brain cortex of these animals. In these studies, I identified 12 genes 
that were differentially expressed in the mouse models with a similar pattern seen 
for levels of 2-AG, synaptamide, and DHA before (Figure 4.12A). Among these 
targeted genes, I confirmed genotype-dependent alterations in the transcript levels 
of Pparg, Mmp9 and Klf10 by quantitative RT-PCR, specifically, a decrease in 
(E4;WT), (E4;KO) and (E3;KO) as compared with (E3;WT) mice. No alterations in 
mRNA levels were observed in (E4;WT) as compared with (E4;KO) animals 
(Figure 4.12B). 
Since loss of sortilin and the presence of E4 affected the expression of PPAR 
targeted genes, I next investigated the consequences of altered PPAR activity for 
neuroinflammatory processes in the brain of aged mice. In the brain, activated 
PPARs have been studied with respect to their anti-inflammatory and anti-
amyloidogenic actions (Bright et al. 2008). For example, treatment of AD mouse 
models with PPAR-γ agonists reduced the expression of pro-inflammatory 
cytokines and caused a concomitant decrease in the numbers of activated 




quantitative RT-PCR to score the transcript levels of genes implicated in brain 






Figure 4.12: The expression of PPAR target genes is altered by sortilin and apoE4 allele in 
the mouse brain. 
(A) Heat map of PPAR target genes using the PPAR Targets RT² Profiler PCR Array (Qiagen). 
Genes are either down- or up-regulated in (E3;WT) mice as compared with the three other 
genotypes (n=3-4 mice per genotype). (B) Quantitative RT-PCR analysis of transcript levels of the 
indicated PPARs target genes in (E3;WT), (E3;KO), (E4;WT), and (E4;KO) mice at 3 months of 
age. The values are given as mean ± SEM of log2 fold changes as compared with (E3;WT) mice 
set to 0 (n=7-8 mice per genotype). The significance of data was determined by Two-way ANOVA, 
followed by Bonferroni post-hoc analysis (*, p<0.05; **, p<0.01; ***, p<0.001). 
In these studies, I detected a significant decrease in mRNA levels of the anti-
inflammatory genes Pparg and vascular endothelial growth factor (Vegf) in 
(E4;WT), (E4;KO) and (E3;KO) compared with (E3;WT) mice (Figure 4.13A).  
In addition, transcript levels of the pro-inflammatory genes tumor necrosis factor 
(Tnfa) and glial fibrillary acidic protein (Gfap) were increased in the three 
genotypes as compared with (E3;WT) animals (Figure 4.13B). A suspected pro-
inflammatory state was confirmed by immunohistological detection of GFAP which 
showed a significant increase in the cortex of (E3;KO) as compared with (E3;WT) 





Figure 4.13: Inflammatory genes are affected by sortilin and APOE genotypes. 
(A, B) Quantitative RT-PCR analysis of transcript levels of the indicated genes in (E3;WT), 
(E3;KO), (E4;WT), and (E4;KO) mice at 18 months of age. The values are given as mean ± SEM of 
log2 fold changes as compared to (E3;WT) mice set to 0 (n=8-10 mice per genotype). The 
significance of data was determined by Two-way ANOVA, followed by Bonferroni post-hoc analysis 
(*, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001). 
4.5. Expression of enzymes in eCBs metabolism are not 
altered in the brain of mice lacking sortilin and with 
apoE4 genotype 
Metabolic enzymes involved in the synthesis and degradation of eCBs are central 
to the regulation of the biological and pathological roles of these lipids. Little is 
known about the biosynthetic pathway that produces synaptamide. However, due 
to its chemical structure, it is believed to be synthesized from DHA by the 




degradation to DHA is executed by fatty acid amide hydrolase (FAAH) (Kim et al. 
2011) (Figure 4.14A).  
2-AG is synthesized by diacylglycerol lipase (DAGL) and degraded 
by monoacylglycerol lipase (MAGL) (Basavarajappa 2007) (Figure 4.14A).  
 
Figure 4.14: Sortilin and APOE isoforms do not affect mRNA levels of enzymes in neuronal 
eCB metabolism. 
(A) Schematic representation of synaptamide and 2-AG metabolism. Synaptamide is produced 
from DHA by N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) that in turn can be 




(DAGL) from diacylglycerol (DAG) and degraded by monoacylglycerol lipase (MAGL) to 
arachidonic acid. (B) Quantitative RT-PCR analysis of transcript levels of the indicated genes in 
brain cortices of (E3;WT), (E3;KO), (E4;WT), and (E4;KO) mice at 3 months of age. The values are 
given as mean ± SEM of log2 fold changes as compared to (E3;WT) mice set to 0 (n=6-9 mice per 
genotype). 
Using quantitative RT-PCR analysis, I failed to document any genotype-dependent 
differences in transcript levels for Napepld, Faah, Dagla, and Mgll in brain cortices 
of  my mouse strains  (Figure 4.14B). These findings argued that changes in levels 
of 2-AG and synaptamide in (E3;KO) or in E4 animals as compared to (E3;WT) 
mice were likely not caused by alterations in neuronal enzyme activities. 
4.6. The extracellular PUFA metabolism is not affected by 
sortilin or APOE genotypes 
In the brain, APOE is secreted by astrocyte and microglia cells to deliver essential 
lipids to neurons in the form of APOE-containing lipoproteins (Holtzman and Herz 
2012). Of note, the three APOE isoforms produced in humans form lipoproteins 
with different size and lipid composition. In detail, apoE4-containing particles have 
a smaller size and are less lipidated than those containing apoE3 or apoE2 
(Cruchaga et al. 2012) (Grimm et al. 2017). Conceptually, alteration in eCB 
content seen in the mouse brain in this study may be explained by the differential 
association of their precursors DHA and ARA with lipoproteins containing E3 or 
E4. To test this hypothesis, I isolated APOE-containing lipoproteins from the 
cerebrospinal fluid of AD patients and healthy controls using heparin affinity 
chromatography (Figure 4.15A). When the lipid content in these lipoprotein 
preparations was measured, no impact of APOE genotype on the levels of DHA or 
ARA were detected in healthy individuals or in AD patients (Figure 4.15B). 
In the CNS, APOE is produced predominantly by astrocytes. Alteration of APOE 
production may explain the changes in lipid homeostasis in the mouse brain. To 
understand if sortilin and/or APOE genotypes may influence APOE production in 
mice, primary astrocytes cultured from new-born mice of the various genotype 





Figure 4.15: APOE-containing brain lipoproteins from healthy individuals or in AD patients 
have a similar PUFA profile. 
(A) Human CSF lipoproteins were subjected to heparin affinity chromatography to separate APOE-
containing from APOE-free lipoproteins. Western blot analysis documents the presence of APOE in 
the heparin-bound (APOE) but not in the column flow-through (non-APOE) fractions. (B) Levels of 
DHA and ARA in APOE-containing lipoproteins isolated from the CSF of healthy controls (CTRL) or 
Alzheimer patients (AD), homozygous for APOE3 (apoE3/3) or APOE4 (apoE4/4). The values are 
given as mean ± SEM (n=7-10 subjects per group). 
Western blot analysis failed to show any obvious alteration in levels of APOE 
isoforms comparing mice with E3 or E4 genotypes, or/and deficient for sortilin 
(Figure 4.16A). Furthermore, levels of APOE mRNA was not changed in these 
primary mouse astrocyte culture (Figure 4.16B). Thus, astrocytes derived from the 





Figure 4.16: Primary astrocytes from the mouse models produce the same amount of APOE. 
(A) Western blot analysis of APOE and sortilin expressed in primary astrocytes of the indicated 
genotype groups. (B) Quantitative RT-PCR analysis of APOE and sortilin transcript levels in 
primary astrocytes derived from (E3;WT), (E3;KO), (E4;WT), or (E4;KO) mouse brains. The values 
are given as mean ± SEM of log2 fold changes as compared to (E3;WT) set to 0. (n=5 cultures per 
genotype). 
4.7. Sortilin affects FABP7 levels in neurons but not in 
glia cells in an APOE-dependent manner 
So far, my analyses of the PUFA metabolism in human and mouse brains, in 




DHA and eCB levels were changed in the mouse brain in response to sortilin and 
APOE isoforms. These findings argued that transport and metabolism of these 
lipids into the extracellular space are not affected by sortilin and APOE genotypes. 
Moreover, the enzymes important for the synthesis and degradation of 
synaptamide and 2-AG were also not altered, suggesting that intracellular 
mechanisms other than enzyme activity may explain these lipid profiles. Sortilin is 
a sorting receptor that directs cargo proteins to various intracellular compartments 
in the biosynthetic and the endocytic pathways (Carlo et al. 2014). Thus, alteration 
of intracellular cargo sorting may explain the lipid imbalance seen in the brain of 
mic lacking this receptor. My hypothesis was supported by work from Dr. Anna 
Malik in Willnow’s laboratory who used an unbiased proteomics approach to 
identify novel targets of sortilin in the neuronal proteome. She reasoned that the 
absence of sortilin may result in aberrant distribution of yet unknown receptor 
ligands between cell surface and intracellular compartments. To identify such 
targets, she biotinylated surface proteins in primary neurons from WT and sortilin 
KO animals. Subsequently, the biotinylated proteins were purified from cell 
extracts using streptavidin beads and subjected to quantitative label-free 
proteomics by LC-MS/MS. By this approach, she identified multiple proteins with 
altered abundance in the neuronal cell surface fraction upon loss of sortilin. 
Among these proteins was one hit with particular relevance for my work, namely 
fatty acid binding protein 7 (FABP7). FABP7 is a member of the fatty acid binding 
proteins, a family of intracellular lipid carriers expressed in various tissues, 
including the brain. These intracellular chaperons facilitate the complex 
intracellular trafficking of fatty acids, essential to control metabolism and action of 
these lipids. FABPs transport a variety of lipid ligands but have favors to bind long-
chain over short-chain PUFAs (Furuhashi and Hotamisligil 2008).  FABP7 is highly 
expressed in the brain and has a strong binding affinity for DHA (Balendiran et al. 
2000).  
To explore whether FABP7 activity may explain the lipid phenotypes seen in my 






Figure 4.17: Sortilin affects FABP7 protein levels in E3 but not in E4 mice. 
(A-B) Western blot analysis of sortilin, FABP7, and GAPDH (loading control) levels in brain cortex 
of the indicated genotype groups. (C-D) Densitometric quantification of FABP7 protein levels in 
(E3;WT), (E3;KO), (E4;WT) and (E4;KO) cortex at 3 months old mice using western blotting as 
exemplified in panels A and B (n=12-18 animals per genotype). Values are mean ± SEM given as 
percent of WT mice set to 100%. Student’s t-test was used to test the significance of differences 




(E4;WT) and (E4;KO) cortex at 3 months old mice. The values are given as mean ± SEM of log2 
fold changes as compared to the respective WT mice set to 0 (n=5-8 animals per genotype). 
Intriguingly, cerebral cortex levels of FABP7 were decreased in (E3;KO) compared 
with (E3;WT) mice (Figure 4.17A-B). No alteration in FABP7 levels was observed 
comparing (E4;WT) with (E4;KO) animals (Figure 4.17C-D). This E3-dependent 
effect of sortilin on brain FABP7 levels was mediated by a post-transcriptional 
mechanism as brain levels of Fabp7 RNA were not altered in (E3;KO) compared 
with (E3;WT) mice, or in (E4;WT) compared to (E4;KO) animals (Figure 4.17E-F). 
 
Figure 4.18: FABP7 protein levels in human brain. 
(A) Western blot analysis of FABP7 levels in prefrontal cortex (PFC) specimens from AD patients 
of the indicated APOE genotypes. Detection of GAPDH was used as loading control. Also, known 
concentrations of recombinant FABP7 produced in CHO cells (CHO Std) were loaded as standard 
curve to enable comparative quantification of FABP7 levels across different western blot 
experiments.  (B) Densitometric quantification of FABP7 protein expression in prefrontal cortex 




Values are mean ± SEM given as percent of the apoE3/3 samples set to 100%. Student’s t-test 
was used to calculate the significance of differences between genotypes (p=0.07). 
The impact of sortilin and APOE genotypes on proteins levels in human or mouse 
brains was specific to FABP7 and not seen for other lipid carriers, such as the 
related carrier FABP5, or FATP1, GPR40, or FACL4. Only the levels of the FA 
translocase, CD36 were decreased in (E4;KO) as compared with (E4;WT) mice 
(Table 4.2). 
Lipid transporter Other name Unpaired t-test 
FABP5 Fatty acid-binding protein 5 n.s. 
CD36 Fatty acid translocase 
** Decrease in (E4;KO) 
vs (E4;WT) 
FATP1 Fatty acid transport protein 1 n.s. 
GPR40 Free fatty acid receptor 1 n.s. 
FACL4 Acyl-CoA synthetase long chain family member 4 n.s. 
 
Table 4.2: Sortilin deficiency impacts levels of CD36 in E4 mice. 
Western blot analysis and densitometric scanning of replicate blots were used to quantify the levels 
of FABP5, CD36, FATP1, GPR40, and FACL4 in the brain cortices of mice either (E3;WT), 
(E3;KO), (E4;WT) or (E4;KO) (primary data not shown). Student’s t-test was used to calculate the 
significance of differences in protein levels comparing genotypes (**p<0.01). 
FABP7 is mainly recognized as a protein highly expressed in astrocytes in the 
developing and mature brain (Matsumata et al. 2016). However, in mouse primary 
astrocyte cultures, FABP7 protein and mRNA levels were not altered comparing 
my four mouse genotype groups (Figure 4.19). This finding argued that the 
differences in FABP7 levels seen in human and mouse brains in my study groups 





Figure 4.19: FABP7 levels are not altered in astrocytes derived from the mouse models. 
(A-B) Western blot analysis of sortilin and FABP7 from primary astrocytes either (E3;WT), (E3;KO), 
(E4;WT) or (E4;KO). Detection of GAPDH and tubulin were used as loading control. (C-D) 
Densitometric quantification of FABP7 protein levels detected by western blotting in replicate 
cultures (n=5 individual cultures per genotype). Values are mean ± SEM given as percent of WT 
astrocyte culture set to 100%. (E-F) Quantitative RT-PCR analysis of Fabp7 transcript levels in 




± SEM of log2 fold changes as compared to the respective WT culture set to 0 (n=5 individual 
cultures per genotype). 
To test this idea, I prepared primary neuronal cultures from new born mice of the 
four genotype groups and quantified levels of FABP7 protein and transcript using 
western blotting or quantitative RT-PCR analyses, respectively. FABP7 protein 
levels were decreased in (E3;KO) as compared with (E3;WT) neuronal cultures 
(Figure 4.20A-B). As in the adult mouse brain, no alteration of FABP7 protein 
levels were observed comparing (E4;WT) with (E4;KO) primary neurons (Figure 
4.20C-D). Moreover, Fabp7 mRNA levels were not altered between the mouse 
genotypes (Figure 4.20C-F). These findings argued that changes in levels of 
FABP7 in the mouse brain are rather specific for neurons than for astrocytes. 
Moreover, a post-translation modification is likely responsible for the FABP7 






Figure 4.20: FABP7 protein levels are altered in sortilin-deficient neurons with E3 allele. 
(A-B) Western blot analysis of sortilin and FABP7 in (E3;WT), (E3;KO), (E4;WT) and (E4;KO) 
primary neuronal cultures. Detection of GAPDH was used as loading control. (C-D) Densitometric 
quantification of replicate western blots for FABP7 protein levels (n=4-8 cultures per genotype). 
Values are mean ± SEM given as percent of the respective WT culture set to 100%. Student’s t-
test was used to calculate the significance of differences between genotypes (*p<0.05).  (E-F) 
Quantitative RT-PCR analysis of Fabp7 transcript levels in (E3;WT), (E3;KO), (E4;WT) and 
(E4;KO) primary neuronal cultures. The values are given as mean ± SEM of log2 fold changes as 
compared to the respective WT culture set to 0 (n=5-10 cultures per genotype). 
4.8. Sortilin interacts with and stabilizes FABP7 
So far, my studies suggested FABP7 as a likely candidate to explain the 
alterations in PUFA content as the decrease in FABP7 levels in neurons lacking 
sortilin reflected the decrease seen for PUFA and eCBs in the mouse brain. Still, 
the mechanism whereby sortilin and FABP7 interacted to control neuronal lipid 
homeostasis remained to be resolved. To do so, I used Chinese hamster ovary 
(CHO) cell lines recombinantly expressing sortilin and FABP7. When CHO cells 
were transiently transfected with a construct encoding for mouse FABP7, levels of 
this carrier were significantly higher in CHO cells stable overexpressing sortilin 
(CHO-S) as compared with parental CHO cells lacking this receptor (Figure 4.21). 
This result was in line with previous experiments in adult mouse brain and in 






Figure 4.21: FABP7 levels are increased in CHO cells overexpressing sortilin. 
(A) Western blot analysis of sortilin and FABP7 levels in parental Chinese hamster ovary (CHO) 
cells or CHO cells stably overexpressing sortilin (CHO-S) and transiently transfected with a 
construct encoding FABP7 and green fluorescence protein (GFP). Detection of tubulin was used as 
loading control. Detection of GFP was used as transfection control. (B) Densitometric quantification 
of FABP7 protein levels in CHO and CHO-S cells as exemplified in panel A (n= 9 replicate 
transfections from 3 independent experiments per cell line).  Values are mean ± SEM given as 
percent of CHO set to 100%. Student’s t-test was used to calculate the significant differences 
between genotypes (**, p<0.01). 
Taken together, the sorting function of sortilin and the decrease of FABP7 levels in 
CHO cells, as well as in adult brain and primary neuronal culture lacking sortilin, 
suggested that sortilin may interact with FABP7 in the sorting of PUFA to various 
intracellular compartments. To test this hypothesis, immunoprecipitation (IP) was 




FABP7 (CHO-S/F) to query a direct interaction of sortilin with this carrier protein 
(Figure 4.22). 
 
Figure 4.22: FABP7 interacts with sortilin in a co-immunoprecipitation (co-IP) assay. 
(A) Western blot analysis of sortilin and FABP7 levels in total cell lysates of CHO cells expressing  
sortilin (CHO-S) or sortilin with myc-tagged mouse FABP7 (CHO-S/F) (INPUT).  (B) Western blot 
analysis of sortilin and FABP7 in immunoprecipitations using anti-myc antibody couple to magnetic 
beads in the cell lysate from CHO-S and CHO-S/F cell lines (FABP7 IP). Co-immunoprecipitation 
of sortilin with FABP7 is seen in lysates from CHO-S/F cells (+) but not from CHO-S cells (+) using 
anti-myc antiserum. No immunoprecipitation of sortilin from CHO-S/F cells or CHO-S cells is 
detected in the absence of anti-myc antiserum (-). 
To prove that sortilin also interacts with FABP7 in intact cells, I applied an 
alternative assay called proximity ligation assay (PLA) that allows the detection of 
the spatial proximity of two proteins in live cells. In detail, PLA employs 
oligonucleotide-conjugated antibodies directed against the target proteins (here 




allows for their hybridization by connector oligonucleotides, forming a circular DNA 
strand that can be amplified by PCR. Incorporation of fluorescence-labelled 
oligonucleotides in the PCR product enables localized detection of protein 
interaction. Using this technique I uncovered that sortilin and FABP7 were 
localized in close proximity based on a PLA signal inside the CHO cells (Figure 
4.23). To understand whether the interaction between sortilin and FABP7 affects 
the half-life of the carrier protein, I next tested FABP7 stability in cells CHO cells. 
In detail, I treated CHO-S/F cells with cycloheximide (CHX), an inhibitor of protein 
translation and monitored the abundance of FABP7 at various time points by 
western blotting. 
Figure 4.23: FABP7 interacts with sortilin in a proximity ligation assay (PLA). 
CHO cells over expressing murine sortilin and FABP7-myc (CHO-S/F) were fixed and treated with 
primary antibodies directed against the two proteins. Subsequently, the cells were incubated with 
secondary PLA-probes, followed by ligation and PCR amplification as detailed in the method 
section. Sortilin and FABP7 interaction as deduced from a positive PLA signal (red) was detected 
by confocal microscopy. Cell nuclei were counterstained with DAPI (blue). As a negative control, 
no PLA signal was seen in cells expressing sortilin only (CHO-S). Scale bar: 50 µm. 
In these experiments, FABP7 levels decreased significantly faster in parental CHO 
cells not expressing sortilin compared to CHO-S cells (Figure 4.24). These 
findings supported my assumption that elevated levels of FABP7 in CHO-S could 




Figure 4.24: Sortilin stabilizes FABP7 protein in CHO cells. 
CHO cells expressing (CHO-S) or lacking sortilin (CHO) were transiently transfected with an 
expression construct encoding FABP7-myc. Forty-eight hours post transfection, the cells were 
treated with 10 µg/ml of cycloheximide and replicate cultures collected at different time points post 
treatment (0, 4, 8, and 12 hours).  The levels of sortilin and FABP7 were determined by western 
blot analysis (A). Detection of tubulin was used as loading control, (B) Densitometric quantification 
of FABP7 levels in CHO and CHO-S cells treated for various time points with cycloheximide. 
Values are mean ± SEM given as percent of FABP7 levels in CHO or CHO-S at 0 hour of 
treatment set to 100% (n= 12 replicate cultures per condition from 3 independent experiments). 
The significance of data was determined by Two-way ANOVA, followed by Bonferroni post-hoc 




4.9. apoE4 alters cellular localization of FABP7 and 
sortilin 
In earlier experiments, I showed that FABP7 levels were decreased in the E3 
condition when sortilin was absent, an effect seen in vivo (Figure 4.17) and ex vivo 
(Figure 4.20). By contrast, absence of sortilin did not impact FABP7 cells with 
apoE4. To test whether E4 differentially impacts intracellular localization of sortilin 
and FABP7 as compared to E3, I treated CHO-S/F cells with exogenous E3 or E4.  
 
Figure 4.25: Production of E3 and E4 in HEK293 cells. 
Western blot analysis of secreted APOE in the medium of HEK293 cells transiently transfected with 
constructs encoding human E3 or E4. The cell medium was conditioned for 48 hours in DMEM in 
the absence of fetal calf serum. Known amounts of commercially obtained recombinant APOE 
(human APOE, MBL) were loaded in parallel (recombinant APOE Std). Densitometric quantification 
of the immunosignals for HEK293-derived APOE as compared to the serial dilutions of 
recombinant human APOE were used to establish the respective concentrations of E3 and E4. 
 




(A) Western blot analysis of sortilin and FABP7 in CHO cells stable overexpressing sortilin and 
FABP7 (CHO-S/F) and treated with E3 or E4 particles. Detection of GAPDH was used as loading 
control. (B) Densitometric quantification of FABP7 levels (n=10 replicate cultures from 4 
independent experiments per cell line).  Values are mean ± SEM given as percent of CHO-S/F 
treated with E3 set to 100%. Student’s t-test was used to calculate the significant differences 
between genotypes (*, p<0.05). 
Lipidated human E3 and E4 were produced by transiently transfecting HEK293 
cells with the respective expression constructs and by collecting the conditioned 
media (Figure 4.25). To assure that the same amounts of E3 and E4 were applied 
to CHO cells, the levels of both APOE isoforms in the preparations were quantified 
by comparing their immune-signal intensities to those of known concentrations of 
recombinant APOE tested in the same western blots (Figure 4.25). When similar 
amounts of APOE were applied exogenously to CHO-S/F, levels of FABP7 
decreased in the E4 compared with the E3 treatment condition (Figure 4.26).  
I previous showed that sortilin, an endocytic protein, binds and stabilizes FABP7, 
thus E4 particles may interfere with the physiological sorting of sortilin and FABP7 






Figure 4.27: Sortilin and FABP7 more strongly co-localize with markers of the early 
endosomes in CHO-S/F cells treated with E4 compared with E3 particles. 
(A) CHO cells stably overexpressing sortilin and murine FABP7 were treated with the same 
amount of E3 or E4 particles. PLA signals for sortilin and FABP7 interaction and immunodetection 
of RAB5, a marker of early endosome are showed in red and green, respectively. Scale bar: 20 
μm. Cell nuclei were counterstained with DAPI (blue). (B) Quantitative co-localization analysis of 
RAB5 and PLA signals as determined by Manders’ coefficient (tM1) calculating the fraction of 
sortilin and FABP7 that overlaps with RAB5 (n=33-35 cells per condition from 3 independent 
experiments). Values are mean ± SEM given as percent of CHO-S/F treated with E3 set to 100%. 
Student’s t-test was used to calculate the significance of differences between treatment conditions 
(**, p<0.01). 
Thus, to test whether E4 may impact sortilin and FABP7 localization, I compared 
the cellular distribution of sortilin-FABP7 complexes (PLA signal) with several 
subcellular markers in CHO-S/F cells treated with exogenous apoE3 or apoE4. 
PLA signals for sortilin and FABP7 showed colocalization with early (RAB5) 
(Figure 4.27) and recycling (RAB11) endosomes (Figure 4.28) in CHO-S/F treated 
with E4 compared with E3 particles. 
In conclusion, my data showed that FABP7, the carrier for DHA and eCB in 
neurons, is controlled by sortilin. Sortilin binds and stabilizes FABP7 allowing the 
proper function of lipid metabolism and actions. However, the presence of the E4 
destabilizes the functional interaction of FABP7 and sortilin by trapping this 





Figure 4.28: Sortilin and FABP7 more strongly co-localize with recycling endosomes in 
CHO-S/F treated with E4 compared with E3 particles. 
(A) CHO cells stably overexpressing sotilin and murine FABP7 were treated with the same amount 
of E3 or E4 particles. The localization of PLA signals, indicating sortilin and FABP7 proximity, and 
RAB11, a marker of recycling endosome are showed in red and green, respectively. Scale bar: 20 
μm. Cell nuclei were counterstained with DAPI (blue). (B) Quantitative co-localization analysis of 
RAB11 and PLA signals as determined by Manders’ coefficient (tM1) calculating the fraction of 
sortilin and FABP7 that overlaps with RAB11 (n=38 cells per condition from 3 independent 
experiments). Values are mean ± SEM given as percent of CHO-S/F treated with E3 set to 100%. 
Student’s t-test was used to calculate the significant differences between genotypes (*p<0.05). 
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5. DISCUSSION 
5.1. APOE-dependent alteration in brain lipid 
homeostasis in mouse and human brains 
The sporadic form of AD is a complex and multifactorial disease caused by a 
combination of genetic and environmental risk factors (Rao et al. 2014), with the 
apoE4 allele as the major underlying genetic risk factor (Corder et al. 1993). Lipid 
homeostasis is clearly altered in AD, as exemplified by aberrant lipid accumulation 
in ependymal cells in the neuronal stem cell niche in post-mortem AD brains and 
in mouse models of AD (Hamilton et al. 2015). Disturbances in genes related to 
lipid metabolism are a marker of aging that may also accelerate AD pathology 
(Podtelezhnikov et al. 2011).  
Given the crucial role of the lipid transporter APOE in control of neuronal 
maturation and synaptogenesis in vitro (Mauch et al. 2001), it is not surprising that 
lipoprotein transport and lipid homeostasis are also considered crucial for normal 
brain function, including neuronal repair, membrane remodeling, and plasticity 
(Holtzman and Herz 2012). For example, altering lipid homeostasis in mice by 
knocking-out the liver X receptors (LXR), a transcription factor important for the 
regulation of cholesterol, fatty acid, and glucose homeostasis, causes severe brain 
abnormalities, including lipid accumulation, loss of neurons, and disorganization of 
myelin sheaths (Wang et al. 2002). Loss of APOE in mice increases the amount of 
sulfatide in the cortex and hippocampus as compared to wild-type mice (Han et al. 
2003). Sulfatide levels in the cortex and hippocampus are also increased in apoE3 
compared with apoE4 transgenic mice. The same effect of APOE is also seen in 
human CSF samples from apoE3 versus apoE4 carriers (Han et al. 2003). 
Conceptually, the activity of APOE in brain lipid homeostasis should critically 
depend on the activity of neuronal APOE receptors, the major pathway to enable 
cellular uptake of lipids bound to this carrier. Not much is known about the link 
between APOE receptors and lipid metabolism. A cholesterol-enriched diet in 
LDLR KO mice leads to a significant decrease in cognitive functions because of 
impaired mitochondrial activity in the cerebral cortex (de Oliveira et al. 2011). 




of cholesterol, sulfatide, galactosylceramide, and triglyceride. These lipid 
alterations coincide with age-dependent dendritic spine degeneration, synapse 
loss, and neuroinflammation (Liu et al. 2010). 
In addition to the LDLR and LRP1, there are other lipoprotein receptors with 
relevance to brain lipid metabolism, such as sortilin. In the periphery, the role of 
sortilin in controlling lipoprotein and lipid homeostasis is well described. Sortilin 
controls plasma cholesterol levels through regulating hepatic lipoprotein 
metabolism and PCSK9 action (Gustafsen et al. 2014) (Strong et al. 2012) 
(Musunuru et al. 2010) (Kjolby et al. 2010). However, sortilin is also highly 
expressed in the CNS where it binds and controls APOE levels as shown by 
accumulation of murine APOE in the brain of mice lacking this receptor (Carlo et 
al. 2013). A role for sortilin in APOE-dependent brain lipid homeostasis is 
supported by findings that sortilin-deficient mice show increased levels of 
sulfatides, a phenotype reported previously for Apoe knock-out animals (Carlo et 
al. 2013) (Han et al. 2003). In unpublished studies preceding my thesis work, Dr. 
Carlo-Spiewok in the Willnow group demonstrated that loss of sortilin also 
increased the brain levels of both human apoE3 and apoE4 in targeted 
replacement mice, arguing that sortilin is a neuronal receptor for murine and 
human APOE species alike. 
In my thesis project, I set out to further elaborate on the role of sortilin in lipid 
homeostasis that may explain the isoform-specific actions of human apoE3 versus 
apoE4 in the risk of sporadic AD. To do this, I used targeted replacement mice 
expressing human apoE3 or apoE4 instead of the murine protein and combined 
them with mouse models genetically deficient for sortilin. APOE replacement mice 
have been commonly used in the field to study human specific aspects of brain 
lipid metabolism and AD progression. For example, mice expressing human 
apoE2 have higher spine density and dendritic complexity compared to the apoE3 
and apoE4 mice (Dumanis et al. 2009). Mice expressing familial AD mutations and 
the apoE4 allele show an increase in oligomer Aβ as compared with apoE3 mice 
(Youmans et al. 2012). Importantly, my studies were performed in 12 weeks old 
adult mice without any trigger of amyloidogenesis such as overexpression of 




without the interference of alterations in lipid homeostasis that may arise 
secondarily as a consequence of aberrant Ab or Tau accumulation. 
Using targeted lipidomics, I documented the impact of sortilin and APOE 
genotypes on lipid profiles. I found a decrease in the omega-3 lipid DHA and in 
synaptamide in mice with the apoE4 allele and in apoE3 mice lacking sortilin 
(Figure 4.4 and Figure 4.5). The alteration of the pool of total fatty acids reflected 
the decrease in DHA (Figure 4.1). Interestingly, levels of omega-6 lipids were not 
altered in the same manner (Figure 4.3). DHA is the main omega-3 lipid present in 
the brain and mice expressing the human apoE4 have decreased DHA levels in 
the cortex compared with apoE2 mice models (Vandal et al. 2014). Moreover, 
DHA intake protects the mouse brain from neurodegeneration (Calon et al. 2004). 
In line with the importance of DHA intake for normal brain function, AD patients 
show a decrease in brain DHA compared to controls (Soderberg et al. 1991) (Yuki 
et al. 2014). Although DHA has been linked to protective effects in the brain, the 
molecular basis of its action remains unknown. An equivalent role in protecting the 
brain from degeneration has been seen for synaptamide. This lipid is a DHA-
derived potent neurogenic and synaptogenic factor with anti-inflammatory potential 
(Park et al. 2016) (Rashid et al. 2013). Since lower concentrations of synaptamide 
are needed to induce hippocampal neurite growth and synaptogenesis than of 
DHA, the neuroprotective effects seen with DHA may actually be mediated by 
synaptamide and not by DHA itself. Thus, DHA may represent the initial pool of 
lipids that can be converted into the active molecule synaptamide to perform its 
neuroprotective functions (Kim et al. 2011).  
As well as for DHA and synaptamide, sortilin- and APOE-dependent changes in 
brain levels were also seen for two eCBs. The eCB system is a lipid-based 
signaling system highly active in the central and peripheral nervous system. It is 
mainly composed of two lipids, anandamide (AEA) and 2-arachidonoylglycerol (2-
AG) (Muccioli 2010). Several research groups have found an increase in 2-AG 
levels but not anandamide in the brain of rodents in response to 
neurodegenerative processes (Van Der Stelt et al. 2006). Similarly, it was shown 
that 2-AG levels were increased in the plasma of AD patients, a mechanism 
thought to antagonize brain damage (Altamura et al. 2015). Consistently, I found 




compared with apoE3 (Figure 4.6). Moreover, I observed a sortilin-dependent 
effect on the levels of OEA and PEA in the brain independent of the APOE 
genotype (Figure 4.6). Taken together, my results strengthen the functional 
interaction of apoE3 and its receptor sortilin in regulating the handling of omega-3 
lipids and eCBs in the brain. 
Although differences in size and lipidation of lipoprotein-containing apoE3 or 
apoE4 have been reported (Heinsinger et al. 2016), I found no alteration DHA and 
arachidonic acids in CSF lipoproteins isolated from in healthy individuals or AD 
patients with apoE3 or apoE4 alleles (Figure 4.15). Furthermore, astrocytes, the 
main cell type in the brain responsible for the expression of APOE produces the 
same amount of APOE regardless of the APOE variant (Figure 4.16). Of clinical 
significance, I also observed the same effect of APOE genotype on 2-AG and 
synaptamide levels in the brain of AD patients compared with controls (Figure 4.7). 
These data, for the first time highlight APOE- and sortilin-dependent alteration of 
the DHA-derived/eCB-like lipid synaptamide in the mouse and human brain 
(Figure 4.5 and Figure 4.7). 
5.2. The consequence of lipid alteration in the brain 
PUFA and the endocannabinoid system have traditionally been viewed 
independently. However, there is a considerable overlap in their effects and it is 
conceivable that these lipids activate similar pathways. The endocannabinoid 
system has been shown to be of key importance in neurodegenerative processes 
due to its anti-inflammatory and neurogenic effects (Molina-Holgado and Molina-
Holgado 2010).  
Anandamide and 2-AG are endogenous signaling lipids that act by binding and 
activating G-protein-coupled-receptors termed CB1 and CB2 (Pertwee and Ross). 
Deletion of both CB receptors causes a decrease in hippocampal progenitor cell 
proliferation (Jin et al. 2004) (Palazuelos et al. 2006). However, despite the 
decrease in some eCBs in sortilin KO mice, adult neurogenesis in the subgranular 
layer of the hippocampal dentate gyrus (DG) and in the subventricular zone (SVZ) 
of the lateral ventricles were not altered in mice lacking sortilin as compared with 
wild-type controls (Figure 4.8 and Figure 4.9). Moreover, sortilin and APOE 




neurons in cortical layers II/III in the mouse brain (Figure 4.10 and Figure 4.11). 
Jointly these results argue that this is not how apoE3 and sortilin work through 
eCBs.  
An alternative mode of action of eCBs is through binding and activation of 
peroxisome proliferator-activated receptors (PPARs) (O’Sullivan 2016). 
Anandamide as well 2-AG bind and activate PPAR-g-dependent transcriptional 
activities resulting in adipocyte differentiation and IL-2 suppression, respectively 
(Bouaboula et al. 2005) (Rockwell et al. 2006). With relevance to my findings, 
synaptamide does not bind to CBs and may thus also act mainly through PPARs. 
Finally, DHA is a natural ligand for PPAR-g (Itoh et al. 2008) (Banga et al. 2009) 
(Niemoller and Bazan 2010). 
PPARs are nuclear proteins that act as transcription factors once they are bound 
by lipid ligands. They regulate the expression of genes with a major role in 
inflammatory responses (Blumberg and Evans 1998). Increased inflammation in 
the brain has a central pathological role in AD. It is an important early component 
in AD that drives AD pathology independent of Aβ deposition (Heppner et al. 
2015) (Tarkowski et al. 2003). For instance, it was shown that mice with age-
associated chronic inflammation develop an AD-like pathology with activated 
microglia in the hippocampus prior to the accumulation of extracellular amyloid 
depositions (Krstic et al. 2012). In addition, aging, the strongest environmental risk 
factor for AD, is also characterized by an aberrant pro-inflammatory state 
(Sparkman and Johnson 2008). In line with a causal role for PPARs in 
containment of brain inflammation, the brain of AD patients is characterized by a 
pro-inflammatory state and by increased oxidative stress that induce 
compensatory protective responses in the brain by increasing PPAR-g transcript 
levels (De La Monte and Wands 2006). Furthermore, non-steroidal anti-
inflammatory drugs (NSAIDs) that act as agonists of PPAR-g exert beneficial 
effects in AD mouse models and patients by attenuating learning deficits and 
memory loss, and by reducing glial activation and amyloid accumulation (Heneka 
et al. 2005) (Pedersen et al. 2006) (Escribano et al. 2010)(Watson et al. 2005). 
In aged apoE3 mice, I found that the absence of sortilin coincides with increased 




mice expressing the receptor. By contrast, no changes in GFAP and TNF-a levels 
were seen in apoE4 expressing mice that expressed or lacked sortilin (Figure 
4.13). Abnormal higher levels of the astrocyte activation marker GFAP were also 
reported in individuals with AD and in AD transgenic mice, suggesting that 
activation of glia are common pathological processes in neurodegenerative 
disorders in humans and animal models (Wyss-Coray 2006) (Liu et al. 2016) 
(Scuderi et al. 2014). Likewise, the pro-inflammatory cytokine TNF-α was also 
shown to have increased levels in the blood, CSF and brain of AD patients 
compared with healthy subjects (Brosseron et al. 2014) (Zhao et al. 2003) 
(Ofengeim et al. 2017). Interestingly, lipopolysaccharide (LPS) injections enhance 
the production of TNF-α in mice expressing apoE4 more than in apoE3 mice 
(Lynch et al. 2003). Synaptamide reduces TNF-α levels in microglia cultures, 
dampening LPS-induced inflammation (Park et al. 2016). These examples 
substantiate apoE4 as a risk of AD and underline the synaptamide-dependent 
neuroprotective role of apoE3 and sortilin. 
Apart from an increase in pro-inflammatory markers GFAP and TNF-α, aged 
mouse models expressing apoE4 or mice expressing apoE3 without sortilin also 
showed transcriptional down-regulation of VEGF compared with (E3;WT) mice 
(Figure 4.13). VEGF is a neuroprotective factor that enhances neuronal survival 
and inhibits the expression of pro-inflammatory cytokines (Xu et al. 2017) (Sun et 
al. 2003). Increasing VEGF levels using encapsulated VEGF nanospheres 
implanted in the brain of mouse models of AD or transgenic mice overexpressing 
VEGF enhances neurogenesis and attenuates Ab-induced AD symptoms (Religa 
et al. 2013) (Herran et al. 2015) (Spuch et al. 2010).  
Jointly, these results argue that PUFA and eCBs can induce PPARs-mediated 
transcription of genes that produce an anti-inflammatory effect. Thus, factors such 
as sortilin and APOE isoforms that alter the metabolism of these lipids may shift 






5.3. The effect of sortilin and APOE isoforms on the 
intracellular lipid carrier FABP7 
Lipid homeostasis in the brain of the mouse models can be perturbed in multiple 
ways, but how do sortilin and APOE isoforms alter lipid metabolism? Conceptually, 
sortilin and APOE genotypes may impact expression of the enzyme repertoire 
involved in metabolism of DHA and/or eCBs. However, I failed to observe any 
alteration in transcript levels of the genes encoding the enzymes Napepld, Faah, 
Dagla, and Mgll in the brain cortices of my mouse strains (Figure 4.14). Therefore, 
alterations in metabolic enzymes are likely not responsible for the alterations in 
levels of these lipids seen in brain tissues of mice and humans with apoE4 as 
compared with apoE3. Moreover, I showed before that sortilin and/or APOE 
isoforms did not impact the types of lipids bound to lipoproteins in plasma or CSF 
(Figure 4.15) (Figure 4.16), disproving altered extracellular lipid transport as the 
underlying cause of APOE-dependent lipid changes seen in the human or mouse 
brain. 
Lipids require specific carriers to facilitate their transport not only in the 
extracellular space but also in the aqueous milieu of the cytoplasm. For the 
later, fatty acid binding proteins (FABPs) have evolved to deliver long-chain fatty 
acids to various compartments of the cell. For example, they transport lipids into 
lipid droplets for storage, to the mitochondria or peroxisome for oxidation, to the 
nucleus to control lipid-mediated transcriptional regulation, or to the extracellular 
space to signal in an autocrine or paracrine manner (Furuhashi and Hotamisligil 
2008).  
Members of the FABP family are expressed in many tissues. Several FABPs are 
expressed in the brain, including FABP3, FABP5 and FABP7. Of these, FABP7 is 
the only carrier affected by sortilin and APOE isoforms and these effects may 
explain the changes in PUFA and eCBs seen in the brains of my mouse models. 
Thus, I found that FABP7 is decreased in the brain of apoE3 mice lacking sortilin. 
This effect was not seen with apoE4 allele (Figure 4.17). The impact of apoE3 and 
sortilin genotypes on FABP7 levels was seen in primary neurons but not in 




interaction of sortilin and FABP7 in neurons that depends on the presence of 
apoE3 (but not apoE4). 
FABP7 is a cytoplasmic shuttle protein that binds DHA with high affinity. Deletion 
of FABP7 decreases DHA levels in the brain (Xu et al. 1996) (Owada et al. 2006). 
FABP7 facilitates cellular uptake, intracellular trafficking, and metabolism of eCBs 
(Kaczocha et al. 2009). Of interest to my studies, FABP7 transports DHA and also 
binds to PPAR-g, thereby inducing expression of GFAP in astrocytes and 
decreasing the migration of malignant glioma cells (Adida and Spener 2006) (Mita 
et al. 2010) (Tripathi et al. 2017).  
Previous studies showed FABP7 levels to be pathologically increased in patients 
with Down’s syndrome or schizophrenia (Sánchez-Font et al. 2003) (Watanabe et 
al. 2007) (Furuhashi and Hotamisligil 2008). Now, I uncovered the relevance of 
this carrier for AD, as I showed a decrease in FABP7 levels in AD patients with 
apoE4 compared to apoE3 carriers (Figure 4.18). 
How exactly may sortilin and APOE genotypes regulate the levels of FABP7 in 
neurons? In my studies, I was unable to detect significant changes in the levels of 
Fabp7 transcript in the brain and in primary neuronal culture of the various mouse 
models. However, a significant decrease in expression at the protein level was 
observed, pointing to post-translation mechanisms being responsible for the 
change in FABP7 protein expression in apoE3 mice or primary cultures lacking 
sortilin as compared with the respective WT control (Figure 4.17; Figure 4.19 and 
Figure 4.20).  
Interestingly, sortilin not only functions as an endocytic receptor at the cell 
membrane but also as an intracellular sorting receptor for the transport of a wide 
variety of intracellular proteins between the trans-Golgi network, endosomes, 
lysosome, and the plasma membrane (Schmidt and Willnow 2016). Thus, I 
hypothesize that sortilin may also be responsible for regulating intracellular sorting 
and stability of FABP7 in cells. I was able to substantiate my hypothesis by 
documenting that FABP7 directly interacts with sortilin (Figure 4.22 and Figure 





Sortilin facilitates uptake of apoE3 and apoE4 to the same extent in vitro (Carlo et 
al. 2013). Also, sortilin-deficient mice accumulate both isoforms in the brain with 
no apparent difference (Dr. Anne-Sophie Carlo-Spiewok, personal 
communication). Jointly, these findings argue that the effect of apoE4 on sortilin 
and FABP7 interaction and on lipid metabolism in neurons works intracellularly. 
This hypothesis is supported by the fact that sortilin mediates the intracellular 
sorting of apolipoprotein B (APOB), regulating nascent lipoprotein particles 
formation and secretion from liver cells (Strong et al. 2012) (Musunuru et al. 2010) 
(Kjolby et al. 2010).  
Interestingly, several studies documented distinct intracellular trafficking pathways 
for apoE3 versus apoE4 that have profound consequences for the activities of 
APOE receptors. Thus, following endocytic uptake by APOE receptors, apoE3 
recycles back to the cell surface for re-secretion. By contrast, apoE4 does not 
recycle but accumulates intracellularly to disrupt cellular functions. For example, in 
hepatoma cells, loss of apoE4 recycling interferes with intracellular cholesterol 
transport (Heeren et al. 2004). Likewise, apoE4 accelerates neuronal 
degeneration and synaptic plasticity or alters brain insulin signaling through the 
impairment of intracellular sorting of the APOE receptor-2 or the insulin receptor, 
respectively (Apoer2) (Zhao et al. 2017) (Chen et al. 2010).  
Receptor-mediated endocytosis is a fundamental process that enables the 
selective uptake of macromolecules into cells. The endocytic pathway is 
necessary for many biological functions, including nutrient uptake, membrane 
remodeling, or control of cell surface receptor signaling. Endocytosis starts with 
the formation of early endosomes by engulfment of sections of the plasma 
membrane containing receptor/ligand complexes. Early endosomes mature to late 
endosomes that fuse with a lysosome (degradation pathway), or target the TGN 
(retrograde trafficking). Early endosomes may also directly move back to the cell 
surface via the recycling pathway (Huotari and Helenius 2011). Alterations in the 
endocytic machinery have been observed in patients and mouse models with AD. 
For example, upregulation of early endosomes marked by RAB5 were seen in the 
hippocampus of people with mild cognitive impairment (MCI) or AD as compared 
with health individuals (Ginsberg et al. 2010). Furthermore, the presence of apoE4 




stages of AD and in aged mice expressing human apoE4 (Cataldo et al. 2000) 
(Zhao et al. 2017). Elevated levels of RAB4-marked recycling endosomes were 
also detected in early stage AD brains (Cataldo et al. 2000). In line with an 
important role of the endocytic machinery in neuronal health, I observed an 
alteration in the intracellular localization of sortilin-FABP7 complexes in CHO-S/F 
cells treated with exogenous apoE3 versus apoE4. PLA signals for sortilin and 
FABP7 showed increased colocalization of both proteins in early (RAB5) (Figure 
4.27) and recycling (RAB11) endosomes (Figure 4.28) in CHO-S/F treated with 
apoE3 particles, confirming an impact of APOE genotypes on sortilin-dependent 
endosomal sorting of FABP7. 
It is possible that different biophysical characteristics of APOE isoforms provide an 
explanation for the altered intracellular sorting of apoE4. The protein contains two 
distinct structural domains, a 22 kDa amino terminal domain that contains the 
LDLR binding site and a second 10 kDa carboxyl terminal domain that binds lipids. 
ApoE3 and apoE4 differ in only one amino acid (cysteine to arginine at position 
112), however, this change has been suggested to underlie the functional 
differences between APOE isoforms. For example, the amino acid change in 
apoE4 in the amino terminal domain influences lipid binding to the other domain 
and, consequently, induces a preference of apoE4 for VLDL instead of HDL. This 
property is called “domain interaction”, whereby changes in one domain are known 
to influence the properties of the other domain (Weisgraber and Mahley 1996). In 
addition, at a lower pH, apoE4 has a greater propensity than apoE3 to form a 
molten globule, a stable folding intermediate that increases lipid binding and 
promotes self-aggregation (Morrow et al. 2002). It was proposed that altering 
endosomal pH by pharmacological or genetic inhibition of NHE6 activity (the 
primary proton leak channel in the early endosome) might be used to recycle 
apoE4 back to the surface of cells. The differences in conformational stability of 
these isoforms may explain why apoE4 is retained in the early and recycling 
compartments, and exerts its detrimental effect on APOE receptor recycling, as 
shown for sortilin herein. 
Taken together, I proposed the following working model for the interaction of 




Under physiological conditions, astrocytes in the brain produce APOE that it is 
secreted into the brain interstitial fluids to form HDL-like lipid transport particles.  
 
Figure 5.1: Proposed model of sortilin, FABP7 and APOE isoforms interaction in neurons. 
(A) In the presence of apoE3-containing lipoprotein particles, interaction of sortilin with FABP7 




Then apoE3 is recycled back to the plasma membrane for re-secretion (Step 3). (B): Loss of 
sortilin in apoE3 mice impairs the trafficking and stability of FABP7 (Step 1) compromising lipid 
metabolism and PPARs function (Step 2), promoting pro-inflammatory effects. (C) Functional 
interaction and sorting of sortilin and FABP7 is disrupted by apoE4 (Step 1) as apoE4 traps sortilin 
inside the cell (Step 2) and it is not recycled back to the plasma membrane (Step 3). Ultimately, 
impairing the function of sortilin in FABP7 sorting has the same detrimental effects on neuronal 
lipid homeostasis as absence of the receptor in KO mice expressing apoE3 (Step 2). 
These lipoprotein particles deliver essential lipids, including PUFA to neurons by 
binding to the APOE receptor, sortilin, which facilitates the endocytosis of APOE-
containing lipoprotein particles. In the presence of apoE3, sortilin interacts with 
FABP7 to control proper intracellular sorting and biosynthesis of PUFAs to 
promote the beneficial actions of DHA, synaptamide, and eCBs. Among other 
modes of action, these lipids regulate PPARs-dependent gene expression, 
protecting the brain from inflammation (Figure 5.1A). Loss of sortilin alters 
trafficking and stability of FABP7 and disrupts its ability to support a proper PUFA 
metabolism, ultimately compromising the actions of lipid ligands on PPARs. 
Impaired activity of PPARs increases pro-inflammatory processes (Figure 5.1B). 
The interaction between sortilin and FABP7 in neuronal lipid homeostasis is lost in 
the presence of apoE4, the most known risk for AD. ApoE4 traps sortilin and 
FABP7 in intracellular endosomes and disrupts their physiological interaction to 
control PUFA and eCBs metabolism and action, ultimately impairing anti-
inflammatory mechanisms mediated by the PPARs.  (Figure 5.1 C). 
5.4. Outlook 
In summary, I found a novel cellular pathway, whereby sortilin, FABP7 and apoE3 
interact to regulate lipid homeostasis and to protect the brain from inflammatory 
and neurodegenerative processes. This protective pathway is disrupted by apoE4, 
potentially contributing to the development of the sporadic forms of AD.  
Certainly, my proposed model raises a number of important questions that 
requires further experimental exploration. Firstly, is DHA or synaptamide the final 
effector for the PPAR-mediated neuroprotection in apoE3? DHA and synaptamide 
are both altered in the same way in brain of my mouse models. Since synaptamide 
is still not well-studied, more experiments are required to understand the role of 




using PPARs-responsive promoters could help in understanding whether 
synaptamide can bind and directly activate the PPARs target genes, and whether 
this function is influenced by sortilin, APOE, and /o FABP7. 
Also, it remains to be substantiated that the interaction of sortilin and FABP7 with 
apoE3 supports a neuroprotective and anti-inflammatory state of the brain, and 
that the disturbances in the PUFA metabolism seen with apoE4 are pro-
inflammatory. For example, using neuronal and glial cultures or brain organoids 
from the various APOE and sortilin genotype groups, it may be possible to perform 
inflammatory cytokines profiling to address this question. Moreover, the use 
CRISPR-Cas9 system to knock-out sortilin, FABP7, APOE isoforms or PPARs in 
brain organoids can be helpful to study their role in the regulation of inflammation 
in a more physiological environment. 
Finally, we need to understand if and how inflammation affects the brain and 
causes neurodegeneration. I showed that aged mice expressing apoE4 or apoE3 
animals lacking sortilin show a pro-inflammatory gene expression profile (Figure 
4.13). To explore the pathophysiological relevance of these expression profiles, 
one may explore the inflammatory propensities of these genotype groups, for 
example by injecting lipopolysaccharide endotoxin (LPS) and by scoring 
accumulation of brain Aβ or neuronal loss induced by this inflammatory insult.  
Although many obstacles still must be overcome before any of these investigations 
can be translated into the clinic to benefit patients at risk of AD, the challenges 
ahead are exciting and my studies demonstrate the potential of lipid biology for 
addressing the pathology of AD. 
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